Thus O
, O
in O
lymphocytes B
, O
growth-affecting O
genes O
other O
than O
immune O
receptors O
risk O
rearrangements O
. O

TNF-alpha O
was O
able O
to O
increase O
expression O
of O
the O
HIV O
LTR O
in O
T B
cells I
, O
but O
in O
monocytic B
cells I
, O
TNF-alpha O
did O
not O
induce O
the O
HIV O
LTR O
above O
a O
constitutive O
level O
of O
activity O
. O

However O
, O
in O
Jurkat O
cells O
, O
TNF-alpha O
dramatically O
enhanced O
the O
spread O
of O
HIV-1 O
through O
the O
cell O
population O
and O
increased O
viral O
RNA O
synthesis O
, O
indicating O
that O
in O
T B
cells I
HIV-1 O
multiplication O
was O
stimulated O
by O
TNF-alpha O
treatment O
. O

Two O
consensus O
sequences O
, O
called O
X O
and O
Y O
boxes O
, O
capable O
of O
binding O
nuclear O
proteins O
and O
regulating O
expression O
in O
B B
cells I
have O
been O
defined O
within O
the O
immediate O
upstream O
region O
of O
major O
histocompatibility O
complex O
( O
MHC O
) O
class O
II O
promoters O
. O

In O
order O
to O
characterize O
the O
function O
of O
cis-acting O
elements O
, O
we O
have O
developed O
an O
in O
vitro O
system O
in O
which O
a O
DRA O
promoter O
construct O
is O
transcribed O
more O
efficiently O
in O
extracts O
from O
B B
cells I
than O
in O
extracts O
from O
class O
II-negative O
HeLa O
cells O
. O

Demonstration O
of O
the O
complete O
dependence O
on O
the O
Y O
box O
in O
this O
system O
suggests O
that O
, O
despite O
its O
demonstrated O
importance O
in O
the O
DRA O
promoter O
, O
the O
DRA O
`` O
octamer O
'' O
does O
not O
utilize O
OTF-2 O
in O
a O
manner O
analogous O
to O
immunoglobulin O
promoters O
in O
B B
cells I
. O

The O
suppression O
of O
basophils B
measured O
as O
whole O
blood O
histamine O
and O
plasma O
cortisol O
concentrations O
was O
assessed O
during O
32 O
hours O
. O

A O
slower O
initial O
decline O
in O
blood O
histamine O
after O
the O
divided O
regimen O
may O
be O
related O
to O
incomplete O
suppression O
of O
basophil B
cell I
return O
to O
blood O
. O

1 O
, O
25 O
( O
OH O
) O
2D2 O
production O
by O
T B
lymphocytes I
and O
alveolar B
macrophages I
recovered O
by O
lavage O
from O
normocalcemic O
patients O
with O
tuberculosis O
. O

To O
compare O
extra-renal O
1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
in O
different O
types O
of O
granulomatous O
disease O
, O
and O
to O
identify O
the O
cell O
types O
responsible O
, O
we O
have O
evaluated O
the O
conversion O
of O
25 O
( O
OH O
) O
D3 O
in O
1 O
, O
25 O
( O
OH O
) O
2D3 O
by O
uncultured B
cells I
recovered O
by O
bronchoalveolar O
lavage O
and O
blood B
mononuclear I
cells I
from O
normocalcemic O
patients O
with O
sarcoidosis O
and O
tuberculosis O
. O

1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
produced O
both O
by O
lavage B
cells I
( O
12/12 O
tuberculosis O
patients O
, O
2/6 O
sarcoidosis O
patients O
) O
and O
blood B
mononuclear I
cells I
( O
3/5 O
tuberculosis O
patients O
, O
0/3 O
sarcoidosis O
patients O
) O
from O
patients O
but O
not O
controls O
, O
but O
significantly O
greater O
amounts O
were O
produced O
by O
lavage O
cells O
from O
tuberculosis O
patients O
than O
those O
of O
sarcoidosis O
patients O
( O
P O
less O
than O
0.001 O
) O
. O

1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
by O
lavage B
cells I
from O
tuberculosis O
patients O
correlated O
with O
the O
number O
of O
CD8+ O
T B
lymphocytes I
present O
but O
not O
other O
cell O
types O
. O

T B
lymphocytes I
appeared O
to O
be O
an O
important O
source O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
, O
since O
purified O
T B
lymphocytes I
from O
all O
patients O
with O
tuberculosis O
produced O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
and O
1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
by O
these O
cells O
correlated O
closely O
with O
that O
produced O
by O
unseparated O
lavage B
cells I
. O

Because O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
improve O
the O
capacity O
of O
macrophages B
to O
kill O
mycobacteria O
, O
our O
results O
support O
the O
conclusion O
that O
macrophage-lymphocyte O
interactions O
, O
mediated O
at O
least O
in O
part O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
may O
be O
an O
important O
component O
of O
a O
successful O
antituberculous O
immune O
response O
. O

Erythroid-specific O
genes O
contain O
binding O
sites O
for O
NF-E1 O
( O
also O
called O
GF-1 O
and O
Eryf-1 O
; O
refs O
1-3 O
respectively O
) O
, O
the O
principal O
DNA-binding O
protein O
of O
the O
erythrocytic B
lineage I
. O

NF-E1 O
expression O
seems O
to O
be O
restricted O
to O
the O
erythrocytic B
lineage I
. O

We O
also O
find O
that O
NF-E2 O
, O
another O
trans-acting O
factor O
of O
the O
erythrocytic B
lineage I
, O
is O
present O
in O
megakaryocytes O
. O

Our O
data O
strengthen O
the O
idea O
of O
a O
close O
association O
between O
the O
erythrocytic O
and O
the O
megakaryocytic O
lineages O
and O
could O
also O
explain O
the O
expression O
of O
markers O
specific O
to O
the O
erythrocytic B
and I
megakaryocytic I
lineages I
in O
most O
erythroblastic O
and O
megakaryoblastic O
permanent O
cell O
lines O
. O

Oestrogen O
receptors O
( O
ER O
) O
are O
present O
in O
neoplastic B
lymphoid I
cells I
and O
have O
been O
considered O
a O
physiological O
marker O
of O
growth O
rate O
or O
differentiation O
. O

Cultured O
MCF-7 O
cells O
, O
derived O
from O
a O
pleural O
effusion O
of O
a O
breast O
cancer O
patient O
, O
known O
to O
contain O
high O
levels O
of O
ER O
were O
used O
as O
a O
positive O
control O
( O
40-48 O
% O
ER B
positive I
cells I
by O
immunocytochemistry O
; O
200 O
fmol/mg O
protein O
by O
EIA O
) O
. O

[ O
Glucocorticoid O
receptors O
in O
peripheral B
blood I
lymphocytes I
of O
patients O
with O
bronchial O
asthma O
] O

Quantitation O
of O
glucocorticoid O
receptors O
( O
GCR O
) O
and O
the O
study O
of O
their O
affinity O
for O
glucocorticosteroids O
( O
GCS O
) O
were O
made O
in O
peripheral B
blood I
lymphocytes I
of O
bronchial O
asthma O
( O
BA O
) O
patients O
in O
consideration O
of O
GCR O
treatment O
and O
serum O
levels O
of O
endogenous O
cortisol O
. O

Glucocorticoids O
are O
known O
to O
have O
a O
lytic O
effect O
in O
leukemic B
cells I
via O
interactions O
with O
the O
glucocorticoid O
receptor O
( O
GR O
) O
. O

In O
mutant O
leukemic B
cells I
resistant O
to O
the O
lytic O
effects O
of O
dexamethasone O
, O
CVZ O
both O
lyses O
the O
cells O
and O
recognizes O
a O
single O
class O
of O
sites O
similar O
to O
the O
high O
affinity O
site O
in O
CEM O
C7 O
cells O
. O

Retroviral O
mediated O
transfer O
and O
expression O
of O
exogenous O
genes O
in O
primary B
lymphoid I
cells I
: O
assaying O
for O
a O
viral O
transactivator O
activity O
in O
normal B
and I
malignant I
cells I
. O

The O
infection O
of O
a O
variety O
of O
cultured O
and O
primary B
lymphoid I
cells I
with O
a O
recombinant O
retrovirus O
containing O
a O
histone O
promoter-driven O
beta-galactosidase O
gene O
is O
shown O
to O
result O
in O
the O
expression O
of O
beta-galactosidase O
in O
50 O
% O
to O
100 O
% O
of O
the O
cells O
. O

A O
similar O
infection O
with O
a O
recombinant O
retrovirus O
containing O
the O
beta-galactosidase O
gene O
with O
an O
adenovirus O
E2 O
promoter O
, O
results O
in O
beta-galactosidase O
activity O
in O
a O
limited O
number O
of O
cultured O
and O
primary B
cells I
. O

The O
drug O
exhibited O
distinct O
normalizing O
effect O
on O
patterns O
of O
calcium O
metabolism O
: O
increase O
of O
total O
and O
ionized O
Ca2+ O
and O
of O
25-OHD O
, O
decrease O
in O
concentration O
of O
parath O
hormone O
and O
osteocalcine O
in O
blood O
serum O
as O
well O
as O
on O
immunological O
parameters O
: O
restoration O
of O
decreased O
content O
of O
T- B
and I
0-lymphocytes I
. O

Concentration O
of O
receptors O
of O
hormonal O
form O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
found O
to O
be O
minimal O
in O
lymphocytes B
under O
conditions O
of O
chronic O
kidney O
insufficiency O
, O
while O
their O
expression O
, O
after O
the O
dioxyvit O
action O
, O
was O
detected O
only O
in O
patients O
with O
glomerulonephritis O
. O

The O
levels O
of O
glucocorticoid O
receptors O
in O
lymphocytes B
of O
the O
patients O
are O
lower O
than O
in O
normal O
subjects O
both O
in O
the O
active O
stage O
of O
the O
disease O
and O
following O
bilateral O
total O
adrenalectomy O
. O

Antigen O
B27 O
seems O
to O
be O
a O
cause O
of O
lower O
levels O
of O
glucocorticoid O
receptors O
in O
blood B
lymphocytes I
. O

Exposure O
of O
RWLeu-4 O
cells O
to O
5 O
nM O
VD3 O
for O
72 O
h O
caused O
50 O
% O
of O
the O
cells O
to O
differentiate O
into O
macrophage/monocyte B
type I
cells I
as O
judged O
by O
nitroblue O
tetrazolium O
staining O
and O
adherence O
to O
plastic O
. O

Progressive O
expression O
of O
cell O
surface O
maturation-specific O
antigens O
of O
the O
monocyte/macrophage B
lineage I
was O
induced O
by O
treatment O
of O
RWLeu-4 O
cells O
with O
VD3 O
for O
24 O
to O
72 O
h O
at O
doses O
that O
inhibited O
cellular O
proliferation O
. O

These O
studies O
suggest O
that O
the O
hXBP-1 O
protein O
acts O
as O
a O
transcription O
factor O
in O
B B
cells I
. O

Absent O
or O
greatly O
diminished O
type O
I O
aldosterone O
receptors O
in O
peripheral B
mononuclear I
leucocytes I
have O
been O
recently O
demonstrated O
and O
explain O
the O
lack O
of O
response O
to O
mineralocorticoids O
. O

In O
the O
four O
families O
with O
an O
autosomal O
dominant O
mode O
of O
transmission O
there O
was O
always O
one O
parent O
with O
reduced O
receptor O
binding O
in O
peripheral B
mononuclear I
leucocytes I
and O
elevated O
serum O
hormone O
levels O
. O

Perceived O
social O
support O
and O
tumor O
estrogen/progesterone O
receptor O
status O
as O
predictors O
of O
natural B
killer I
cell I
activity O
in O
breast O
cancer O
patients O
. O

This O
report O
is O
concerned O
with O
the O
prediction O
of O
natural O
killer B
( I
NK I
) I
cell I
activity O
in O
61 O
Stage O
I O
and O
II O
breast O
cancer O
patients O
, O
between O
the O
ages O
of O
25 O
and O
70 O
, O
who O
were O
accrued O
to O
this O
project O
. O

[ O
Estrogen O
receptor O
content O
of O
peripheral B
blood I
lymphocytes I
in O
patients O
with O
systemic O
lupus O
erythematosus O
] O

ER O
content O
in O
lymphocytes B
of O
peripheral O
blood O
from O
27 O
SLE O
patients O
and O
20 O
healthy O
controls O
were O
determined O
by O
dextran-coated O
charcoal O
assay O
. O

ER O
content O
in O
lymphocytes B
of O
each O
sample O
was O
expressed O
by O
both O
fmol/mg O
of O
lymphocyte O
cytosolic O
protein O
and O
fmol/micrograms O
of O
lymphocyte O
DNA O
. O

The O
results O
showed O
that O
there O
was O
no O
significant O
difference O
between O
the O
ER O
content O
of O
lymphocytes B
from O
the O
controls O
and O
that O
from O
patients O
with O
SLE O
. O

But O
the O
logarithmic O
mean O
of O
ER O
content O
in O
lymphocytes B
, O
expressed O
by O
fmol/mg O
of O
cytosolic O
protein O
, O
in O
14 O
patients O
with O
active O
SLE O
( O
0.9356 O
+/- O
0.31 O
) O
was O
significantly O
higher O
than O
that O
in O
13 O
patients O
with O
inactive O
SLE O
( O
0.2979 O
+/- O
0.23 O
, O
P O
less O
than O
0.001 O
) O
and O
in O
the O
controls O
( O
0.6204 O
+/- O
0.52 O
, O
P O
less O
than O
0.001 O
) O
. O

The O
normal O
upper O
limit O
of O
ER O
content O
in O
lymphocytes B
, O
expressed O
by O
fmol/micrograms O
of O
DNA O
, O
was O
0.136 O
. O

The O
elevated O
rate O
of O
ER O
content O
in O
lymphocytes B
in O
14 O
active O
SLE O
( O
92.9 O
% O
) O
was O
also O
higher O
than O
that O
in O
quieiescent O
patients O
( O
23.1 O
% O
, O
P O
less O
than O
0.001 O
) O
and O
in O
the O
controls O
( O
10 O
% O
, O
P O
less O
than O
0.001 O
) O
. O

An O
in O
vitro O
globin O
gene O
switching O
model O
based O
on O
differentiated B
embryonic I
stem I
cells I
. O

We O
used O
mouse B
embryonic I
stem I
( I
ES I
) I
cells I
to O
study O
globin O
gene O
expression O
and O
switching O
in O
vitro O
. O

We O
show O
that O
ES-derived B
embryoid I
bodies I
express O
the O
full O
complement O
of O
mouse O
embryonic O
globin O
genes O
in O
the O
correct O
temporal O
order O
and O
that O
on O
further O
differentiation O
, O
a O
switch O
occurs O
to O
the O
fetal/adult O
genes O
. O

In O
addition O
, O
the O
erythroid-specific O
transcription O
factor O
NF-E1 O
was O
shown O
to O
be O
expressed O
coordinately O
with O
that O
of O
globin O
in O
embryoid B
bodies I
. O

We O
have O
cloned O
and O
characterized O
a O
mitogen-inducible O
gene O
isolated O
from O
human B
T I
cells I
that O
predicts O
a O
protein O
of O
968 O
amino O
acids O
. O

Extrarenal O
receptor-effector-mechanisms O
for O
aldosterone O
: O
the O
sequence O
of O
effects O
on O
the O
cellular O
electrolyte O
transport O
in O
human B
lymphocytes I
and O
their O
implications O
for O
disorders O
of O
the O
water O
and O
electrolyte O
balances O
. O

High O
affinity O
aldosterone O
binding O
sites O
have O
not O
only O
been O
described O
in O
the O
classic O
target O
tissues O
such O
as O
the O
renal O
tubules O
, O
but O
also O
in O
non-classic O
target O
tissues O
such O
as O
the O
hippocampus O
, O
mammary O
gland O
, O
endothelial B
cells I
and O
, O
recently O
, O
human B
mononuclear I
leukocytes I
. O

An O
in O
vitro O
effect O
of O
aldosterone O
on O
intracellular O
sodium O
, O
potassium O
and O
calcium O
concentrations O
and O
cell O
volume O
was O
shown O
in O
human B
mononuclear I
leukocytes I
. O

The O
clinical O
significance O
of O
this O
model O
was O
underlined O
by O
the O
demonstration O
of O
absent O
or O
a O
decreased O
number O
of O
mineralocorticoid O
receptors O
and O
the O
lack O
of O
electrolyte O
response O
to O
aldosterone O
in O
human B
mononuclear I
leukocytes I
of O
patients O
with O
pseudohypoaldosteronism O
and O
aldosteronism O
. O

Additionally O
, O
an O
abnormal O
effector O
mechanism O
could O
be O
demonstrated O
in O
human B
mononuclear I
leukocytes I
from O
essential O
hypertensives O
. O

Immunohistochemical O
study O
of O
steroid O
hormones O
and O
an O
estrogen O
binding O
assay O
in O
malignant B
soft I
tissue I
tumors I
. O

Immunohistochemically O
, O
the O
immunoreaction O
against O
5 O
steroid O
hormone O
anti-sera O
( O
estradiol O
, O
estriol O
, O
cortisol O
, O
progesterone O
and O
testosterone O
) O
was O
examined O
in O
39 O
cases O
with O
the O
malignant B
soft I
tissue I
tumors I
( O
fibrosarcoma O
: O
8 O
, O
malignant O
fibrous O
histiocytoma O
: O
6 O
, O
rhabdomyosarcoma O
: O
10 O
, O
leiomyosarcoma O
: O
10 O
, O
liposarcoma O
: O
5 O
) O
. O

Immunostained B
tumor I
cells I
were O
more O
frequently O
distributed O
in O
the O
area O
where O
tumor O
cell O
infiltration O
was O
more O
invasive O
. O

We O
concluded O
that O
steroid O
hormones O
might O
be O
closely O
related O
to O
tumor O
cell O
infiltration O
of O
some O
malignant B
soft I
tissue I
tumors I
. O

This O
inhibitor O
did O
not O
affect O
protein O
kinase O
C O
-mediated O
gene O
transcription O
, O
suggesting O
that O
cyclic O
AMP-dependent O
protein O
kinases O
are O
involved O
in O
the O
signal O
transduction O
pathway O
for O
IL-1 O
in O
a O
number O
of O
responsive B
cell I
types I
. O

Nuclear O
3 O
, O
5 O
, O
3'-triiodothyronine O
receptors O
( O
T3R O
) O
of O
circulating B
human I
lymphocytes I
in O
hyper- O
and O
hypothyroidism O
and O
nonthyroidal O
diseases O
. O

The O
clinical O
implications O
of O
nuclear O
T3R O
alterations O
of O
circulating B
lymphocytes I
in O
hyperthyroidism O
, O
hypothyroidism O
and O
nonthyroidal O
diseases O
were O
investigated O
. O

Nuclear O
T3R O
in O
lymphocytes B
was O
determined O
by O
radio-ligand O
binding O
analysis O
. O

In O
the O
patients O
with O
diabetes O
mellitus O
, O
chronic O
renal O
failure O
and O
hepatic O
cirrhosis O
, O
the O
nuclear O
T3R O
MBC O
of O
lymphocytes B
was O
about O
1.5-1.6 O
times O
of O
the O
normal O
controls O
. O

A O
primary O
site O
of O
infection O
by O
human O
adenoviruses O
is O
lymphoid B
cells I
. O

However O
, O
analysis O
of O
the O
viral O
control O
elements O
and O
the O
cellular O
factors O
that O
regulate O
adenoviral O
gene O
expression O
in O
lymphocytes B
has O
not O
been O
reported O
. O

To O
determine O
whether O
different O
cellular O
factors O
were O
involved O
in O
E3 O
regulation O
in O
lymphocytes B
as O
compared O
with O
HeLa O
cells O
, O
both O
DNA O
binding O
and O
transfection O
analysis O
with O
the O
E3 O
promoter O
in O
both O
cell O
types O
were O
performed O
. O

Transfections O
of O
E3 O
constructs O
linked O
to O
the O
chloramphenicol O
acetyltransferase O
gene O
revealed O
that O
mutagenesis O
of O
the O
distal O
NF-kappa O
B O
motif O
( O
L2 O
) O
had O
minimal O
effects O
on O
promoter O
expression O
in O
HeLa O
cells O
, O
but O
resulted O
in O
dramatic O
decreases O
in O
expression O
by O
lymphoid B
cells I
. O

In O
contrast O
, O
mutagenesis O
of O
proximal O
NF-kappa O
B O
motif O
( O
L1 O
) O
had O
minimal O
effects O
on O
gene O
expression O
in O
both O
HeLa O
cells O
and O
lymphoid B
cells I
but O
resulted O
in O
a O
small O
, O
but O
reproducible O
, O
increase O
in O
gene O
expression O
in O
lymphoid B
cells I
when O
coupled O
to O
the O
L2 O
mutation O
. O

Defensin O
resistance O
is O
not O
the O
only O
virulence O
characteristic O
controlled O
by O
the O
PhoP-PhoQ O
regulon O
because O
mutations O
in O
pagC O
, O
as O
well O
as O
ones O
in O
the O
phoP O
locus O
that O
resulted O
in O
constitutive O
pag O
activation O
( O
phenotype O
PhoPc O
) O
, O
had O
no O
effect O
on O
defensin O
resistance O
, O
even O
though O
they O
rendered O
the O
organism O
avirulent O
and O
deficient O
in O
survival O
within O
macrophages B
. O

The O
virulence O
defect O
conferred O
by O
mutations O
in O
the O
phoP O
-phoQ O
two-component O
regulatory O
system O
is O
not O
completely O
explained O
by O
alterations O
in O
resistance O
to O
cationic O
proteins O
and O
involves O
the O
control O
of O
other O
proteins O
necessary O
for O
S. O
typhimurium O
survival O
within O
macrophages B
. O

Our O
finding O
that O
induction O
of O
NF-kappa O
B O
by O
tumor O
necrosis O
factor O
or O
antibody O
to O
CD3 O
is O
not O
sufficient O
to O
induce O
HIV O
enhancer O
-dependent O
transcription O
in O
cloned O
T O
cells O
contrasts O
with O
results O
obtained O
in O
most O
lymphoblastoid O
T-cell O
lines O
and O
indicates O
that O
normal O
T B
lymphocytes I
differ O
from O
tumoral B
T I
cells I
in O
terms O
of O
requirements O
for O
HIV O
LTR O
activation O
. O

Decreased O
concentration O
of O
1 O
, O
25-dihydroxyvitamin O
D3 O
receptors O
in O
peripheral B
mononuclear I
cells I
of O
patients O
with O
X-linked O
hypophosphatemic O
rickets O
: O
effect O
of O
phosphate O
supplementation O
. O

Mammalian B
cells I
express O
two O
distinct O
forms O
of O
transcription O
factor O
CREB O
( O
cAMP O
response O
element O
binding O
protein O
) O
that O
are O
apparently O
the O
products O
of O
alternative O
splicing O
of O
the O
CREB O
gene O
transcript O
. O

We O
show O
that O
both O
CREB O
isoforms O
are O
expressed O
in O
many B
cell I
types I
and O
mammalian O
species O
. O

The O
vpr O
product O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
acts O
in O
trans O
to O
accelerate O
virus O
replication O
and O
cytopathic O
effect O
in O
T B
cells I
. O

Its O
expression O
appears O
to O
be O
activated O
during O
pro-B-cell O
development O
, O
is O
abundant O
at O
the O
pre-B- O
and O
mature O
B-cell O
stages O
, O
but O
is O
absent O
in O
terminally B
differentiated I
plasma I
cells I
. O

Antibodies O
are O
produced O
exclusively O
in O
B B
lymphocytes I
. O

The O
expression O
of O
the O
antibody-encoding O
genes O
, O
the O
immunoglobulin O
( O
Ig O
) O
genes O
, O
is O
also O
restricted O
to O
B B
cells I
. O

The O
Oct-1 O
protein O
is O
present O
in O
all O
cell O
types O
analyzed O
so O
far O
, O
whereas O
Oct-2A O
and O
Oct-2B O
are O
found O
mainly O
in O
B B
lymphocytes I
. O

A O
factor O
known O
to O
bind O
to O
endogenous O
Ig O
heavy O
chain O
enhancer O
only O
in O
lymphocytes B
is O
a O
ubiquitously O
active O
transcription O
factor O
. O

It O
is O
present O
in O
an O
active O
form O
in O
both O
B B
cells I
and O
non-B B
cells I
, O
where O
it O
can O
mediate O
transcriptional O
activation O
in O
vitro O
and O
in O
vivo O
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected O
reporter O
gene O
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous O
Ig O
heavy O
chain O
enhancer O
in O
non-lymphoid B
cells I
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF-muE3 O
, O
was O
detected O
in O
B B
cells I
but O
not O
in O
non-B B
cells I
. O

From O
this O
and O
other O
findings O
the O
picture O
emerges O
that O
there O
are O
at O
least O
three O
categories O
of O
factors O
which O
mediate O
cell-type-specific O
transcription O
in O
B B
lymphocytes I
: O
( O
a O
) O
cell-specific O
factors O
such O
as O
Oct-2A O
and O
Oct-2B O
that O
are O
not O
expressed O
in O
most O
other O
cell O
types O
: O
( O
b O
) O
ubiquitous O
factors O
such O
as O
NF-kappa O
B O
that O
are O
constitutively O
active O
in O
B B
cells I
but O
are O
sequestered O
in O
an O
inactive O
form O
in O
other O
cells O
; O
( O
c O
) O
ubiquitously O
active O
factors O
, O
exemplified O
by O
the O
one O
binding O
to O
the O
E3 O
sequence O
motif O
. O

This O
factor O
is O
present O
in O
an O
active O
form O
in O
a O
variety O
of O
cell O
types O
but O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous O
Ig O
heavy O
chain O
enhancer O
in O
non-B B
cells I
, O
perhaps O
due O
to O
a O
non-permissive O
chromatin O
structure O
of O
the O
Ig O
heavy O
chain O
locus O
. O

A O
study O
was O
made O
of O
adrenocortical O
function O
by O
measuring O
blood O
plasma O
cortisol O
concentration O
and O
amount O
of O
glucocorticoid O
receptors O
in O
lymphocytes B
as O
well O
as O
thyroid O
function O
by O
measuring O
blood O
plasma O
triidothyronine O
and O
thyroxine O
concentration O
in O
58 O
bronchial O
asthma O
children O
aged O
1 O
to O
14 O
years O
. O

TAR O
independent O
activation O
of O
the O
human O
immunodeficiency O
virus O
in O
phorbol O
ester O
stimulated O
T B
lymphocytes I
. O

The O
clinical O
course O
and O
the O
laboratory O
data O
suggest O
that O
the O
tachycardia O
crises O
are O
the O
consequence O
of O
a O
hypersensitivity O
of O
the O
heart O
to O
thyroid O
hormones O
, O
associated O
with O
an O
increased O
number O
of O
T3 O
nuclear O
receptor O
sites O
in O
lymphocytes B
. O

Induction O
of O
immediate O
early O
response O
genes O
by O
macrophage O
colony-stimulating O
factor O
in O
normal B
human I
monocytes I
. O

We O
have O
investigated O
the O
induction O
of O
these O
genes O
by O
macrophage-CSF O
( O
M-CSF O
) O
in O
human B
monocytes I
that O
do O
not O
proliferate O
in O
response O
to O
M-CSF O
but O
require O
the O
factor O
for O
optimal O
cell O
differentiation O
. O

Normal O
human B
monocytes I
were O
isolated O
, O
carefully O
washed O
, O
and O
incubated O
for O
36 O
to O
48 O
h O
in O
fetal O
bovine O
serum-containing O
medium O
. O

At O
the O
end O
of O
this O
incubation O
the O
resting B
cells I
were O
stimulated O
with O
M-CSF O
, O
and O
RNA O
was O
isolated O
for O
analysis O
by O
Northern O
blotting O
. O

RNA O
from O
control O
resting B
cells I
contained O
low O
to O
undetectable O
levels O
of O
c-jun O
, O
fibronectin O
receptor O
, O
and O
actin O
mRNA O
. O

Therefore O
, O
in O
normal B
human I
monocytes I
M-CSF O
induces O
immediate O
early O
response O
genes O
without O
inducing O
cell O
proliferation O
. O

Inducible O
nuclear O
factor O
binding O
to O
the O
kappa O
B O
elements O
of O
the O
human O
immunodeficiency O
virus O
enhancer O
in O
T B
cells I
can O
be O
blocked O
by O
cyclosporin O
A O
in O
a O
signal-dependent O
manner O
. O

To O
better O
understand O
the O
molecular O
mechanisms O
underlying O
suppression O
by O
CsA O
, O
we O
have O
investigated O
the O
effects O
of O
this O
drug O
on O
transcription O
factors O
in O
T B
cells I
. O

The O
differentiation O
of O
T B
cells I
into O
functionally O
diverse O
subpopulations O
is O
controlled O
in O
part O
, O
by O
transcriptional O
activation O
and O
silencing O
; O
however O
, O
little O
is O
known O
in O
detail O
about O
the O
proteins O
that O
influence O
this O
developmental O
process O
. O

Tandem O
AP-1-binding O
sites O
within O
the O
human O
beta-globin O
dominant O
control O
region O
function O
as O
an O
inducible O
enhancer O
in O
erythroid B
cells I
. O

Purified O
OTF1 O
from O
HeLa O
cells O
and O
OTF1 O
and O
OTF2 O
from O
B B
cells I
bound O
to O
identical O
sequences O
within O
the O
heavy-chain O
promoter O
. O

The O
expression O
of O
the O
gene O
encoding O
the O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
is O
induced O
upon O
activation O
of O
T B
cells I
with O
phytohemagglutinin O
and O
active O
phorbolester O
and O
upon O
expression O
of O
tax1 O
, O
a O
transactivating O
protein O
of O
the O
human O
T-cell O
leukemia O
virus O
type O
I O
. O

Effects O
of O
mitogenic O
agents O
upon O
glucocorticoid O
action O
in O
human B
tonsillar I
T-lymphocytes I
. O

The O
treatment O
of O
human B
tonsillar I
T-lymphocytes I
with O
4-phorbol O
12-myristate O
13-acetate O
( O
PMA O
) O
, O
resulted O
in O
about O
two O
fold O
increase O
in O
glucocorticoid O
receptor O
( O
GR O
) O
number O
, O
without O
any O
significant O
change O
in O
the O
receptor O
affinity O
. O

Two O
distinct O
signal O
transmission O
pathways O
in O
T B
lymphocytes I
are O
inhibited O
by O
complexes O
formed O
between O
an O
immunophilin O
and O
either O
FK506 O
or O
rapamycin O
. O

Proliferation O
and O
immunologic O
function O
of O
T B
lymphocytes I
are O
initiated O
by O
signals O
from O
the O
antigen O
receptor O
that O
are O
inhibited O
by O
the O
immunosuppressant O
FK506 O
but O
not O
by O
its O
structural O
analog O
, O
rapamycin O
. O

Adherence O
is O
an O
important O
initial O
step O
in O
the O
transition O
of O
a O
circulating B
monocyte I
to O
a O
tissue B
macrophage I
. O

The O
increased O
PDGF O
( O
B O
) O
mRNA O
observed O
in O
adherent B
monocytes I
was O
accompanied O
by O
increases O
in O
mRNAs O
of O
the O
early O
growth O
response O
genes O
c-fos O
( O
maximal O
at O
20 O
min O
) O
, O
c-jun O
, O
and O
EGR2 O
( O
maximal O
at O
6-24 O
h O
) O
. O

Stimulation O
of O
T B
lymphocytes I
through O
their O
antigen O
receptor O
leads O
to O
the O
appearance O
of O
several O
transcription O
factors O
, O
including O
NF-AT O
and O
NF-kappa O
B O
, O
which O
are O
involved O
in O
regulating O
genes O
required O
for O
immunologic O
activation O
. O

To O
investigate O
the O
activity O
of O
a O
single O
transcription O
factor O
in O
individual B
viable I
cells I
, O
we O
have O
applied O
an O
assay O
that O
uses O
the O
fluorescence-activated O
cell O
sorter O
to O
quantitate O
beta-galactosidase O
( O
beta-gal O
) O
. O

We O
have O
analyzed O
the O
distribution O
of O
NF-AT O
transcriptional O
activity O
among O
T B
cells I
undergoing O
activation O
by O
using O
a O
construct O
in O
which O
three O
tandem O
copies O
of O
the O
NF-AT-binding O
site O
directs O
transcription O
of O
the O
lacZ O
gene O
. O

We O
investigated O
the O
regulation O
of O
the O
promoter O
( O
BMRF1 O
) O
for O
this O
early O
gene O
by O
studying O
its O
responsiveness O
in O
vitro O
to O
two O
immediate-early O
viral O
transactivators O
, O
BZLF1 O
( O
Z O
) O
and O
BRLF1 O
( O
R O
) O
, O
focusing O
on O
the O
differences O
in O
response O
in O
lymphoid B
cells I
and O
epithelial B
cells I
. O

In O
lymphoid B
cells I
, O
Z O
or O
R O
alone O
produced O
only O
small O
increases O
in O
EA-D O
promoter O
activity O
, O
whereas O
both O
transactivators O
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
epithelial B
cells I
, O
the O
Z O
transactivator O
alone O
produced O
maximal O
stimulation O
of O
the O
EA-D O
promoter O
; O
the O
effect O
of O
R O
and O
Z O
together O
was O
no O
greater O
than O
that O
of O
Z O
alone O
. O

Deletional O
analysis O
and O
site-directed O
mutagenesis O
of O
the O
EA-D O
promoter O
demonstrated O
that O
in O
epithelial B
cells I
the O
potential O
AP-1 O
binding O
site O
plays O
an O
essential O
role O
in O
Z O
responsiveness O
, O
although O
sequences O
further O
upstream O
are O
also O
important O
. O

In O
lymphoid B
cells I
, O
only O
the O
upstream O
sequences O
are O
required O
for O
transactivation O
by O
the O
Z/R O
combination O
, O
and O
the O
AP-1 O
site O
is O
dispensable O
. O

In O
this O
study O
, O
we O
isolated O
a O
cDNA O
coding O
for O
FK506-binding O
protein O
( O
FKBP O
) O
from O
human O
peripheral O
blood O
T B
cells I
by O
using O
mixed O
20-mer O
oligonucleotide O
probes O
synthesized O
on O
the O
basis O
of O
the O
sequence O
, O
Glu-Asp-Gly-Lys-Lys-Phe-Asp O
, O
reported O
for O
bovine O
FKBP O
. O

In O
Northern O
blot O
analysis O
, O
mRNA O
species O
of O
approximately O
1.8 O
kilobases O
that O
hybridized O
with O
human O
FKBP O
cDNA O
were O
detected O
in O
poly O
( O
A O
) O
+ O
RNAs O
from O
brain O
, O
lung O
, O
liver O
, O
and O
placental B
cells I
and O
leukocytes B
. O

We O
demonstrate O
that O
the O
NF-microB-binding O
site O
plays O
a O
critical O
role O
in O
the O
IgH O
enhancer O
, O
because O
mutation O
of O
the O
microB O
DNA O
motif O
decreased O
transcriptional O
activity O
of O
the O
IgH O
enhancer O
in O
cells O
of O
the O
B-cell B
lineage I
but O
not O
in O
nonlymphoid B
cells I
. O

Moreover O
, O
combined O
mutation O
of O
both O
microB O
and O
OCTA O
sites O
further O
reduced O
enhancer O
activity O
in O
lymphoid B
cells I
. O

Interestingly O
, O
alteration O
of O
either O
the O
microB O
or O
E3 O
site O
in O
a O
70-base-pair O
fragment O
of O
the O
IgH O
enhancer O
that O
lacks O
the O
binding O
site O
for O
OCTA O
abolished O
enhancer O
activity O
in O
lymphoid B
cells I
completely O
. O

This O
inducer O
can O
act O
in O
concert O
with O
the O
HIV-2 O
tat O
gene O
and O
T-cell O
activation O
in O
enhancing O
gene O
expression O
in O
human B
CD4+ I
lymphocytes I
. O

Deletion O
mutation O
analysis O
of O
the O
HIV-2 O
long O
terminal O
repeat O
( O
LTR O
) O
suggests O
that O
the O
element O
that O
responds O
to O
CMV O
transactivation O
in O
human B
CD4+ I
lymphocytes I
is O
either O
a O
diffuse O
one O
or O
located O
downstream O
of O
the O
HIV-2 O
enhancer O
element O
. O

Quantitative O
immunohistochemical O
analysis O
of O
mononuclear B
infiltrates I
in O
breast O
carcinomas O
-- O
correlation O
with O
tumour O
differentiation O
. O

Inflammatory B
infiltrates I
were O
analysed O
in O
tissue O
sections O
of O
76 O
breast O
carcinomas O
by O
counting O
the O
percentage O
of O
macrophages B
, O
IgA+ B
and I
IgG+ I
plasma I
cells I
, O
T B
cells I
with O
their O
subpopulations O
, O
and O
natural B
killer I
cells I
, O
and O
by O
measuring O
postcapillary O
venules O
( O
PCVs O
, O
found O
in O
12 O
cases O
) O
within O
the O
infiltrates O
. O

In O
addition O
, O
a O
direct O
correlation O
exists O
between O
the O
diameter O
of O
the O
PCVs O
and O
both O
the O
percentage O
of O
the O
OKT8+ O
T O
cells O
( O
P O
less O
than O
0.04 O
) O
and O
the O
Leu-7+ O
natural B
killer I
cells I
( O
P O
less O
than O
0.03 O
) O
. O

In O
this O
study O
we O
present O
evidence O
for O
reactivity O
of O
pregnancy B
lymphocytes I
, O
but O
not O
nonpregnancy B
lymphocytes I
, O
with O
the O
progesterone O
receptor-specific O
monoclonal O
antibody O
mPRI O
. O

Using O
an O
avidin O
-biotin O
peroxidase O
detection O
system O
, O
we O
found O
a O
nuclear O
staining O
in O
14.6 O
+/- O
3.7 O
% O
( O
mean O
+/- O
SEM O
, O
N O
= O
27 O
) O
of O
pregnancy B
lymphocytes I
, O
while O
only O
0.47 O
+/- O
0.33 O
% O
( O
mean O
+/- O
SEM O
, O
N O
= O
15 O
) O
of O
nonpregnancy B
lymphocytes I
reacted O
with O
the O
antibody O
. O

In O
nonpregnancy O
lymphocytes O
a O
3-day O
PHA O
treatment O
, O
as O
well O
as O
allogeneic O
stimulation O
, O
resulted O
in O
a O
significant O
increase O
in O
the O
number O
of O
receptor-containing B
cells I
. O

Glucocorticoid O
receptors O
on O
mononuclear B
leukocytes I
in O
Alzheimer O
's O
disease O
. O

In O
an O
exploration O
of O
the O
potential O
role O
of O
the O
glucocorticoid O
receptor O
( O
GR O
) O
in O
AD O
, O
GR O
density O
and O
affinity O
were O
assessed O
on O
mononuclear B
leukocytes I
of O
12 O
AD O
patients O
and O
12 O
healthy O
controls O
. O

Oncogene O
amplification O
correlates O
with O
dense O
lymphocyte O
infiltration O
in O
human O
breast O
cancers O
: O
a O
role O
for O
hematopoietic O
growth O
factor O
release O
by O
tumor B
cells I
? O

The O
interleukin O
2 O
( O
IL-2 O
) O
gene O
promoter O
is O
recognized O
by O
several O
cell-type-specific O
and O
ubiquitous O
transcriptional O
regulators O
that O
integrate O
information O
transmitted O
by O
various O
signaling O
systems O
leading O
to O
IL-2 O
production O
and O
T-cell B
activation O
. O

Elevated O
glucocorticoid O
receptor O
concentrations O
before O
and O
after O
glucocorticoid O
therapy O
in O
peripheral B
mononuclear I
leukocytes I
of O
patients O
with O
atopic O
dermatitis O
. O

The O
number O
and O
affinity O
of O
glucocorticoid O
binding O
sites O
in O
peripheral B
mononuclear I
leukocytes I
of O
patients O
with O
atopic O
dermatitis O
( O
AD O
) O
and O
healthy O
controls O
were O
determined O
under O
baseline O
conditions O
and O
after O
a O
defined O
oral O
glucocorticoid O
treatment O
. O

The O
actions O
of O
cyclosporin O
A O
and O
FK506 O
suggest O
a O
novel O
step O
in O
the O
activation O
of O
T B
lymphocytes I
. O

Cyclosporin O
A O
and O
FK506 O
are O
immunosuppressive O
compounds O
that O
have O
similar O
inhibitory O
effects O
on O
the O
expression O
of O
several O
lymphokines O
produced O
by O
T B
lymphocytes I
. O

Rex O
acts O
posttranscriptionally O
to O
facilitate O
accumulation O
of O
full-length O
gag/pol O
and O
singly O
spliced O
env O
mRNA O
in O
the O
cytoplasm O
of O
HTLV-infected B
cells I
. O

Astrocytes B
and O
glioblastoma B
cells I
express O
novel O
octamer-DNA O
binding O
proteins O
distinct O
from O
the O
ubiquitous O
Oct-1 O
and O
B O
cell O
type O
Oct-2 O
proteins O
. O

The O
'octamer O
' O
sequence O
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin O
genes O
in O
B-lymphocytes B
as O
well O
as O
a O
number O
of O
housekeeping O
genes O
in O
all O
cell O
types O
. O

In O
lymphocytes B
, O
the O
octamer-binding O
protein O
Oct-2A O
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B-cell O
specific O
gene O
expression O
, O
while O
the O
ubiquitous O
protein O
Oct-1 O
seems O
to O
control O
general O
octamer O
site O
-dependent O
transcription O
. O

Using O
the O
electrophoretic O
mobility O
shift O
assay O
, O
at O
least O
six O
novel O
octamer O
binding O
proteins O
were O
detected O
in O
nuclear O
extracts O
of O
cultured B
mouse I
astrocytes I
. O

In O
melanoma B
cells I
that O
contain O
the O
N-Oct-3 O
factor O
, O
a O
transfected O
lymphocyte-specific O
promoter O
was O
neither O
activated O
nor O
was O
it O
repressed O
upon O
contransfection O
with O
an O
Oct-2A O
expression O
vector O
. O

Detection O
in O
non-erythroid B
cells I
of O
a O
factor O
with O
the O
binding O
characteristics O
of O
the O
erythroid O
cell O
transcription O
factor O
EF1 O
. O

Here O
we O
report O
the O
presence O
of O
a O
factor O
with O
the O
mobility O
and O
sequence-specific O
DNA-binding O
characteristics O
of O
EF1 O
at O
low O
abundance O
in O
a O
wide O
variety O
of O
non-erythroid B
cell I
types I
. O

This O
is O
the O
first O
report O
of O
an O
EF1 O
-like O
activity O
in O
non-erythroid B
cells I
and O
indicates O
that O
this O
factor O
may O
play O
a O
role O
in O
the O
regulation O
of O
genes O
expressed O
in O
such O
cells O
. O

The O
expression O
of O
CD4 O
, O
a O
marker O
for O
T-derived B
lymphoid I
cells I
, O
was O
not O
significantly O
different O
in O
serum-free O
medium O
. O

[ O
Glucocorticoid O
receptors O
on O
human B
peripheral I
mononuclear I
and I
polymorphonuclear I
leucocytes I
: O
changes O
in O
patients O
with O
yang-deficiency O
] O

It O
was O
found O
that O
, O
in O
former O
works O
, O
the O
glucocorticoid O
receptors O
( O
GCR O
) O
on O
peripheral B
mixed I
leucocytes I
in O
patients O
with O
Yang-deficiency O
were O
decreased O
. O

In O
this O
work O
, O
the O
mixed B
leucocytes I
were O
further O
separated O
into O
mononuclear B
( I
MNL I
) I
and I
polymorphonuclear I
( I
PML I
) I
leucocytes I
, O
and O
GCR O
were O
determined O
in O
each O
part O
of O
leucocytes B
. O

GCR O
on O
MNL B
and O
PML B
in O
6 O
Yang O
deficient O
patients O
were O
3473 O
+/- O
413 O
and O
4433 O
+/- O
651 O
sites/cell O
respectively O
, O
statistically O
significant O
from O
the O
normal O
control O
group O
( O
4462 O
+/- O
962 O
and O
5622 O
+/- O
782 O
sites/cell O
respectively O
, O
P O
less O
than O
0.05 O
) O
. O

GCR O
on O
MNL B
, O
PML B
and O
mixed B
leucocytes I
in O
5 O
patients O
were O
determined O
simultaneously O
, O
and O
all O
lowered O
from O
the O
control O
group O
. O

The O
results O
were O
3369 O
+/- O
370 O
, O
4986 O
+/- O
419 O
and O
4524 O
+/- O
852 O
sites/cell O
respectively O
, O
with O
the O
lowest O
GCR O
on O
MNL B
and O
highest O
on O
PML B
. O

In O
vitro O
binding O
of O
aldosterone O
to O
mineralocorticoid O
receptors O
on O
human B
mononuclear I
leukocytes I
( O
HML B
) O
and O
its O
effects O
on O
the O
intracellular O
sodium O
and O
potassium O
concentrations O
of O
HML B
have O
already O
been O
described O
. O

In O
only O
four O
patients O
sodium O
in O
HML B
without O
incubation O
was O
elevated O
compared O
with O
the O
range O
for O
normal O
persons O
. O

The O
independence O
of O
intracellular O
electrolytes O
from O
aldosterone O
despite O
a O
normal O
number O
of O
mineralocorticoid O
receptors O
may O
reflect O
an O
impairment O
of O
the O
mineralocorticoid O
effector O
mechanism O
in O
the O
HML B
of O
patients O
with O
essential O
hypertension O
. O

[ O
Differential O
diagnostic O
value O
of O
receptors O
of O
1 O
, O
25-dihydroxyvitamin O
D3 O
( O
calcitriol O
) O
determination O
in O
lymphocytes B
of O
children O
with O
rickets O
and O
rickets-like O
diseases O
] O

The O
authors O
provide O
the O
results O
of O
studying O
1 O
, O
25-dihydroxyvitamin O
D3 O
( O
calcitriol O
) O
in O
lymphocytes B
of O
children O
with O
rickets O
and O
rickets-like O
diseases O
. O

The O
plasma O
cortisol O
concentration O
and O
the O
sites O
of O
glucocorticoid O
receptor O
( O
GCR O
) O
in O
the O
peripheral B
lymphocytes I
were O
measured O
in O
32 O
healthy O
aged O
persons O
and O
13 O
young O
adults O
. O

In O
animal O
experiment O
, O
GCR O
of O
spleen B
lymphocytic I
cell I
was O
also O
measured O
in O
18 O
aged O
rats O
and O
9 O
young O
rats O
. O

Cytoplasmic O
protein O
extracts O
from O
chronic B
myelogenous I
leukemia I
( I
CML I
) I
cells I
contained O
an O
activity O
that O
altered O
the O
electrophoretic O
mobility O
of O
complexes O
formed O
between O
nuclear O
proteins O
and O
the O
transcriptional O
enhancers O
of O
interferon O
( O
IFN O
) O
-inducible O
genes O
. O

Exposure O
of O
CML B
cells I
to O
IFN-alpha O
diminished O
the O
effect O
of O
the O
CML O
cytoplasmic O
proteins O
on O
these O
nuclear O
protein-DNA O
complexes O
. O

The O
expression O
of O
c-fos O
, O
c-jun O
, O
and O
c-myc O
genes O
is O
regulated O
by O
heat O
shock O
in O
human B
lymphoid I
cells I
. O

The O
effect O
of O
heat O
shock O
on O
the O
expression O
of O
the O
nuclear O
protooncogenes O
c-fos O
, O
c-jun O
, O
and O
c-myc O
was O
studied O
in O
human B
lymphoid I
cells I
. O

These O
results O
demonstrate O
that O
the O
transcription O
of O
nuclear O
protooncogenes O
is O
regulated O
by O
heat O
shock O
indicating O
a O
role O
for O
nuclear O
protooncogenes O
in O
the O
stress O
response O
of O
lymphoid B
cells I
. O

[ O
The O
inhibitory O
effect O
of O
hydrocortisone O
on O
the O
chemotactic O
migration O
of O
human B
leukocytes I
] O

Random O
migration O
( O
RM O
) O
and O
chemotactic O
migration O
( O
ChtM O
) O
of O
human B
leukocytes I
to O
yeast O
activated O
serum O
were O
studied O
with O
the O
modified O
Boyden O
chamber O
method O
. O

Leukocytes B
migrated O
most O
rapidly O
at O
night O
. O

It O
is O
suggested O
that O
glucocorticoids O
( O
GC O
) O
may O
be O
a O
physiological O
regulator O
of O
the O
activity O
of O
leukocytes B
and O
its O
inhibitory O
action O
on O
ChtM O
may O
be O
involved O
in O
antiinflammatory O
mechanisms O
of O
GC O
of O
pharmacological O
doses O
. O

Response O
to O
T B
cell I
activation O
signals O
. O

T B
cell I
activation O
results O
in O
high O
levels O
of O
HIV O
replication O
and O
is O
thought O
to O
be O
one O
mechanism O
leading O
to O
the O
conversion O
from O
latent O
to O
active O
viral O
infection O
. O

These O
qualitative O
differences O
in O
the O
response O
to O
T B
cell I
activation O
are O
reproduced O
not O
only O
when O
HIV-1 O
or O
HIV-2 O
enhancers O
are O
placed O
upstream O
of O
a O
heterologous O
promoter O
but O
also O
when O
these O
enhancers O
are O
switched O
between O
their O
respective O
LTR O
. O

Their O
constitutive O
expression O
is O
limited O
to O
B B
lymphocytes I
and O
thymic B
epithelial I
cells I
. O

Radioreceptor O
assay O
of O
some O
corticosteroid O
derivatives O
in O
human B
mononuclear I
leukocytes I
. O

Several O
new O
4 O
, O
19-substituted O
steroids O
and O
previously O
synthesized O
corticosteroids O
were O
assayed O
for O
affinity O
to O
type O
1 O
receptors O
in O
human B
mononuclear I
leukocytes I
. O

When O
tested O
in O
a O
radioreceptor O
assay O
in O
human B
mononuclear I
leukocytes I
the O
synthesized O
compounds O
showed O
only O
low O
relative O
binding O
affinities O
( O
RBA O
) O
to O
type O
1 O
receptor O
, O
the O
highest O
being O
0.72 O
% O
for O
13 O
( O
aldosterone O
= O
100 O
% O
) O
. O

Cell O
type O
specificity O
and O
activation O
requirements O
for O
NFAT-1 O
( O
nuclear O
factor O
of O
activated B
T-cells I
) O
transcriptional O
activity O
determined O
by O
a O
new O
method O
using O
transgenic O
mice O
to O
assay O
transcriptional O
activity O
of O
an O
individual O
nuclear O
factor O
. O

Nuclear O
factor O
of O
activated B
T-cells I
( O
NFAT-1 O
) O
is O
a O
transcription O
factor O
which O
is O
considered O
to O
be O
an O
important O
regulator O
in O
early O
T-cell O
activation O
. O

NFAT-1 O
activity O
had O
previously O
been O
thought O
to O
be O
confined O
to O
activated B
T-lymphocytes I
upon O
release O
of O
intracellular B
calcium I
. O

Besides O
in O
T-lymphocytes B
NFAT-1 O
activity O
could O
also O
be O
induced O
in O
T-lymphocyte-depleted B
spleen I
cells I
and O
purified B
B-lymphocytes I
and O
requires O
agents O
that O
both O
release O
intracellular O
calcium O
and O
activate O
protein O
kinase O
C O
. O

A O
difference O
in O
the O
time O
course O
of O
appearance O
of O
NFAT-1 O
activity O
between O
T-lymphocytes B
and O
non-T-lymphocytes B
was O
revealed O
. O

A O
7-base-pair O
mutation O
in O
the O
site O
B O
palindrome O
, O
which O
destroyed O
protein O
binding O
, O
resulted O
in O
increased O
expression O
from O
the O
human O
immunodeficiency O
virus O
type O
1 O
long O
terminal O
repeat O
in O
T B
cells I
. O

Progesterone O
suppression O
of O
pregnancy B
lymphocytes I
is O
not O
mediated O
by O
glucocorticoid O
effect O
. O

This O
study O
investigated O
whether O
the O
suppressive O
effect O
of O
progesterone O
on O
pregnancy B
lymphocytes I
is O
mediated O
by O
specific O
progesterone O
receptors O
. O

In O
a O
study O
of O
cellular O
proteins O
involved O
in O
the O
transcriptional O
regulation O
of O
murine O
retroviruses O
in O
T B
lymphocytes I
, O
we O
have O
discovered O
that O
a O
member O
of O
the O
ets O
gene O
family O
encodes O
a O
sequence-specific O
DNA-binding O
protein O
. O

Transcriptional O
efficiency O
of O
the O
MSV O
LTR O
promoter O
containing O
this O
disrupted O
ets-1 O
binding O
site O
was O
compared O
to O
the O
activity O
of O
a O
wild-type O
promoter O
in O
mouse B
T I
lymphocytes I
in O
culture O
, O
and O
15- O
to O
20-fold O
reduction O
in O
expression O
of O
a O
reporter O
gene O
was O
observed O
. O

Type O
II O
estrogen O
binding O
sites O
in O
human B
peripheral I
blood I
mononuclear I
cells I
: O
variations O
during O
the O
menstrual O
cycle O
. O

We O
have O
previously O
reported O
that O
human B
peripheral I
blood I
mononuclear I
cells I
( O
PBMC B
) O
contain O
type O
II O
estrogen O
binding O
sites O
( O
type O
II O
EBS O
) O
. O

Tamoxifen O
was O
also O
found O
to O
compete O
with O
17 O
beta-estradiol O
for O
type O
II O
EBS O
in O
PBMC B
, O
although O
to O
a O
lesser O
extent O
than O
diethylstilbestrol O
. O

Mononuclear B
leukocyte I
glucocorticoid O
receptor O
binding O
characteristics O
and O
down-regulation O
in O
major O
depression O
. O

To O
study O
whether O
this O
represents O
glucocorticoid O
( O
GC O
) O
resistance O
, O
[ O
3H O
] O
-DEX-binding O
assays O
were O
used O
to O
measure O
, O
in O
vitro O
, O
the O
GC O
receptor O
affinity O
( O
1/Kd O
) O
and O
number O
( O
Bmax O
) O
in O
mononuclear B
leukocytes I
of O
11 O
MDD O
patients O
and O
15 O
control O
subjects O
. O

Ras-related O
GTP-binding O
proteins O
and O
leukocyte B
signal O
transduction O
. O

Many O
aspects O
of O
leukocyte B
function O
are O
regulated O
by O
both O
heterotrimeric O
and O
Ras-related O
GTP-binding O
proteins O
, O
but O
there O
is O
little O
definite O
information O
about O
their O
roles O
in O
the O
specialized O
processes O
utilized O
by O
leukocytes B
for O
cell O
killing O
. O

Proteins O
exist O
in O
leukocytes B
able O
to O
modify O
GTP-binding O
protein O
function O
in O
this O
manner O
, O
and O
their O
activity O
may O
be O
regulated O
by O
signals O
generated O
on O
phagocyte O
stimulation O
. O

BSAP O
: O
a O
key O
regulator O
of O
B-cell B
development O
and O
differentiation O
. O

B-cell-specific O
activator O
protein O
( O
BSAP O
) O
is O
a O
recently O
identified O
member O
of O
the O
Pax-gene O
family O
of O
transcription O
factors O
; O
in O
the O
lymphoid O
system O
, O
BSAP O
is O
produced O
only O
in O
B B
cells I
. O

They O
propose O
that O
BSAP O
is O
a O
key O
protein O
of O
B B
cells I
and O
that O
it O
not O
only O
influence O
B-cell O
development O
but O
also O
influences O
the O
balance O
between O
B-cell O
proliferation O
and O
immunoglobulin O
secretion O
at O
later O
stages O
of O
B-cell O
differentiation O
. O

The O
murine O
BCL6 O
gene O
is O
induced O
in O
activated B
lymphocytes I
as O
an O
immediate O
early O
gene O
. O

The O
chromosomal O
translocation O
involving O
3q27 O
is O
often O
detected O
in O
human B
B-cell I
lymphomas I
, O
especially O
diffuse O
lymphomas O
with O
a O
large-cell O
component O
. O

Furthermore O
, O
it O
was O
induced O
in O
lymphocytes B
activated O
with O
phorbol O
ester O
and O
Ca2+ O
ionophore O
within O
30 O
min O
after O
stimulation O
. O

These O
results O
suggest O
that O
BCL6 O
plays O
a O
role O
in O
activated B
lymphocytes I
as O
an O
immediate O
early O
gene O
. O

These O
results O
reveal O
that O
HSF3 O
is O
negatively O
regulated O
in O
avian B
cells I
and O
acquires O
DNA-binding O
activity O
in O
certain O
cells O
upon O
heat O
shock O
. O

Activation O
and O
expression O
of O
the O
nuclear O
factors O
of O
activated B
T I
cells I
, O
NFATp O
and O
NFATc O
, O
in O
human B
natural I
killer I
cells I
: O
regulation O
upon O
CD16 O
ligand O
binding O
. O

The O
putative O
factors O
that O
couple O
the O
signal O
transduction O
from O
surface O
receptors O
to O
the O
activation O
of O
cytokine O
synthesis O
in O
natural B
killer I
( I
NK I
) I
cells I
have O
not O
been O
elucidated O
. O

We O
report O
here O
that O
the O
nuclear O
factor O
of O
activated B
T I
cells I
( O
NFATp O
) O
, O
a O
cyclosporin O
A O
( O
CsA O
) O
-sensitive O
factor O
that O
regulates O
the O
transcription O
of O
several O
cytokines O
, O
mediates O
CD16 O
-induced O
activation O
of O
cytokine O
genes O
in O
human B
NK I
cells I
. O

CD16 O
( O
Fc O
gamma O
RIIIA O
) O
-induced O
expression O
of O
cytokine O
mRNA O
in O
NK B
cells I
occurs O
via O
a O
CsA-sensitive O
and O
Ca O
( O
2+ O
) O
-dependent O
mechanism O
. O

Stimulation O
of O
NK B
cells I
with O
CD16 O
ligands O
induces O
NFAT O
-like O
DNA O
binding O
activity O
in O
the O
nuclear O
extracts O
from O
these O
cells O
, O
as O
detected O
in O
electrophoretic O
mobility O
shift O
assays O
. O

NK O
cell O
NFAT O
is O
present O
in O
the O
cytosol O
of O
nonstimulated B
cells I
, O
migrates O
to O
the O
nucleus O
upon O
stimulation O
, O
and O
can O
associate O
with O
AP-1 O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp- O
and O
NFATc- O
specific O
antibodies O
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 O
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp O
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T B
lymphocytes I
. O

NK B
cells I
do O
not O
express O
NFATc O
constitutively O
, O
but O
NFATc O
mRNA O
accumulation O
is O
induced O
in O
these O
cells O
within O
2 O
h O
of O
stimulation O
with O
CD16 O
ligands O
. O

These O
results O
provide O
the O
first O
direct O
evidence O
that O
both O
CsA-sensitive O
transcription O
factors O
, O
NFATp O
and O
NFATc O
, O
are O
expressed O
in O
human O
NK B
cells I
, O
and O
that O
their O
activation O
and/or O
expression O
can O
be O
regulated O
in O
primary O
cells O
by O
a O
single O
stimulus O
, O
that O
, O
in O
the O
case O
of O
CD16 O
in O
NK B
cells I
, O
results O
in O
early O
activation O
of O
NFATp O
and O
subsequently O
induced O
expression O
of O
NFATc O
mRNA O
. O

One O
of O
the O
most O
important O
cytokines O
involved O
in O
immune O
response O
regulation O
is O
interleukin O
2 O
( O
IL-2 O
) O
, O
a O
potent O
activator O
of O
the O
proliferation O
and O
function O
of O
T B
lymphocytes I
and O
natural B
killer I
cells I
. O

Exposure O
of O
activated O
human B
T I
lymphocytes I
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL-2 O
leads O
to O
the O
phosphorylation O
of O
Stat1 O
alpha O
, O
Stat1 O
beta O
, O
and O
Stat3 O
, O
as O
well O
as O
of O
two O
Stat-related O
proteins O
, O
p94 O
and O
p95 O
. O

Peripheral B
blood I
mononuclear I
cells I
( O
pbmc B
) O
and O
bone B
marrow I
cells I
of O
26 O
patients O
were O
examined O
for O
c-fos O
, O
c-myc O
, O
p53 O
and O
the O
hybrid O
bcr/abl O
mRNA O
levels O
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c-fos O
transcript O
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN-alpha O
therapy O
( O
p O
< O
0.01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes B
( O
r O
= O
0.6895 O
, O
p O
< O
0.01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature B
cells I
( O
r O
= O
-0.568 O
, O
p O
< O
0.01 O
) O
contained O
in O
the O
pbmc B
preparations O
tested O
, O
( O
ii O
) O
constitutive O
mRNA O
levels O
of O
the O
hybrid O
bcr/abl O
, O
c-myc O
and O
p53 O
are O
positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN-alpha O
is O
accompanied O
by O
upregulation O
of O
c-fos O
and O
downregulation O
of O
c-myc O
mRNA O
levels O
in O
responder O
patients O
. O

Menopause O
is O
associated O
with O
a O
significant O
increase O
in O
blood O
monocyte O
number O
and O
a O
relative O
decrease O
in O
the O
expression O
of O
estrogen O
receptors O
in O
human B
peripheral I
monocytes I
. O

PROBLEM O
: O
The O
clinical O
significance O
of O
the O
differential O
expression O
of O
estrogen O
receptor O
( O
ER O
) O
in O
human B
monocytes I
was O
evaluated O
. O

RESULTS O
: O
During O
menopause O
there O
is O
a O
significant O
decrease O
in O
the O
percentage O
of O
ER B
positive I
monocytes I
, O
and O
an O
increase O
in O
blood B
monocyte I
number O
, O
which O
declines O
following O
estrogen O
replacement O
therapy O
to O
values O
of O
the O
young O
. O

CONCLUSIONS O
: O
These O
findings O
suggest O
that O
estrogen O
modulates O
the O
monocyte B
numbers O
and O
its O
effects O
may O
be O
mediated O
through O
the O
ER O
in O
the O
monocytes B
. O

Staphylococcal O
enterotoxins O
( O
SE O
) O
stimulate O
T B
cells I
expressing O
the O
appropriate O
variable O
region O
beta O
chain O
of O
( O
V O
beta O
) O
T-cell O
receptors O
and O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
several O
autoimmune O
diseases O
. O

Depending O
on O
costimulatory O
signals O
, O
SE O
induce O
either O
proliferation O
or O
anergy O
in O
T B
cells I
. O

In O
contrast O
to O
hematopoietic B
cells I
, O
I O
kappa O
B O
alpha-/- O
embryonic O
fibroblasts O
show O
minimal O
constitutive O
NF-kappa O
B O
, O
as O
well O
as O
normal O
signal-dependent O
NF-kappa O
B O
activation O
that O
is O
concomitant O
with O
I O
kappa O
B O
beta O
degradation O
. O

Our O
results O
indicate O
that O
I O
kappa O
b O
beta O
, O
but O
not O
I O
kappa O
B O
alpha O
, O
is O
required O
for O
the O
signal-dependent O
activation O
of O
NF-kappa O
B O
in O
fibroblasts B
. O

However O
, O
I O
kappa O
B O
alpha O
is O
required O
for O
the O
postinduction O
repression O
of O
NF-kappa O
B O
in O
fibroblasts B
. O

Interleukin-7 O
can O
induce O
the O
activation O
of O
Jak O
1 O
, O
Jak O
3 O
and O
STAT O
5 O
proteins O
in O
murine O
T B
cells I
. O

In O
human B
peripheral I
blood I
mononuclear I
cells I
( O
PBMC B
) O
stimulated O
with O
OKT3/PMA O
, O
tepoxalin O
inhibited O
lymphocyte B
proliferation O
with O
an O
IC50 O
of O
6 O
microM O
. O

These O
data O
suggest O
that O
the O
action O
of O
tepoxalin O
to O
inhibit O
proliferation O
in O
PBMC B
may O
be O
at O
least O
in O
part O
due O
to O
its O
ability O
to O
reduce O
the O
amount O
of O
available O
iron O
resulting O
in O
decreased O
activation O
of O
NF O
kappa O
B O
and O
subsequent O
inhibition O
of O
cytokine O
production O
. O

Microtubules O
mediate O
cellular O
25-hydroxyvitamin O
D3 O
trafficking O
and O
the O
genomic O
response O
to O
1 O
, O
25-dihydroxyvitamin O
D3 O
in O
normal O
human B
monocytes I
. O

Although O
immunocytochemistry O
has O
shown O
that O
disruption O
of O
microtubular O
assembly O
prevents O
nuclear O
access O
of O
the O
sterol-VDR O
complex O
, O
the O
role O
of O
microtubules O
in O
the O
response O
to O
1 O
, O
25 O
( O
OH O
) O
2D3 O
has O
not O
been O
studied O
in O
viable B
cells I
. O

Our O
studies O
examined O
this O
interaction O
in O
normal O
human B
monocytes I
. O

Interestingly O
, O
microtubule O
disruption O
also O
decreased O
monocyte B
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
, O
not O
by O
decreasing O
the O
Vmax O
of O
monocyte O
mitochondrial O
1 O
alpha-hydroxylase O
but O
through O
an O
increase O
in O
the O
Km O
for O
25 O
( O
OH O
) O
2D3 O
. O

Relationship O
between O
Rap1 O
protein O
phosphorylation O
and O
regulation O
of O
Ca2+ O
transport O
in O
platelets B
: O
a O
new O
approach O
. O

Then O
, O
we O
studied O
platelets B
of O
patients O
with O
congestive O
heart O
failure O
for O
their O
expression O
of O
the O
potential O
97 O
kDa O
Ca O
( O
2+ O
) O
-ATPase O
target O
of O
regulation O
through O
the O
Rap1 O
protein O
as O
well O
as O
the O
phosphorylation O
of O
the O
Rap1 O
protein O
using O
the O
catalytic O
subunit O
of O
the O
cyclic O
AMP-dependent O
protein O
kinase O
( O
C. O
Sub O
. O
) O
. O

These O
results O
allowed O
us O
to O
use O
these O
pathological O
platelets B
to O
study O
the O
relationship O
between O
the O
expression O
of O
Rap1 O
protein O
and O
the O
regulation O
of O
Ca2+ O
transport O
by O
selecting O
a O
patient O
with O
severe O
heart O
failure O
. O

Besides O
the O
evidence O
for O
regulation O
of O
the O
expression O
of O
the O
Rap1 O
protein O
in O
platelets B
from O
patients O
with O
heart O
failure O
, O
these O
findings O
constitute O
a O
new O
approach O
in O
favour O
of O
the O
regulation O
of O
platelet O
Ca2+ O
transport O
through O
the O
phosphorylation O
of O
the O
Rap1 O
protein O
. O

The O
tumour O
suppressor O
p53 O
has O
been O
shown O
to O
regulate O
this O
type O
of O
apoptosis O
in O
thymocytes B
, O
but O
an O
as O
yet O
unknown O
, O
p53 O
-independent O
pathway O
( O
s O
) O
appears O
to O
mediate O
the O
same O
event O
in O
mitogen-activated O
mature O
T O
lymphocytes O
. O

Here O
we O
show O
DNA O
damage-induced O
apoptosis O
in O
these O
T B
lymphocytes I
is O
dependent O
on O
the O
antioncogenic O
transcription O
factor O
interferon O
regulatory O
factor O
( O
IRF O
) O
-1 O
. O

Thus O
two O
different O
anti-onco-genic O
transcription O
factors O
, O
p53 O
and O
IRF-1 O
, O
are O
required O
for O
distinct O
apoptotic O
pathways O
in O
T B
lymphocytes I
. O

Circadian O
rhythm O
of O
glucocorticoid O
receptors O
in O
human B
peripheral I
leukocytes I
and O
their O
reactivity O
to O
glucocorticoids O
. O

1 O
) O
There O
exists O
a O
CR O
of O
GR O
in O
human B
leukocytes I
, O
PMN B
, O
and O
monocytes B
with O
the O
peak O
values O
from O
0400 O
to O
0800 O
hr O
and O
the O
trough O
values O
between O
2300 O
and O
0000 O
hr O
. O

2 O
) O
The O
FI O
of O
the O
chemotactic O
migration O
rate O
of O
PMN B
by O
cortisol O
also O
showed O
diurnal O
changes O
which O
were O
synchronous O
with O
that O
of O
GR O
. O

Productive O
infection O
of O
T B
cells I
with O
human O
immunodeficiency O
virus O
1 O
( O
HIV-1 O
) O
typically O
requires O
that O
the O
T B
cells I
be O
stimulated O
with O
antigens O
or O
mitogens O
. O

Recently O
, O
we O
have O
found O
that O
vigorous O
replication O
of O
HIV-1 O
takes O
place O
in O
nonactivated O
memory B
T I
cells I
after O
syncytium O
formation O
with O
dendritic B
cells I
( O
DCs B
) O
. O

These O
syncytia O
lack O
activated B
cells I
as O
determined O
by O
an O
absence O
of O
staining O
for O
Ki-67 O
cell O
cycle O
antigen O
. O

The O
expression O
and O
activity O
of O
NF-kappa O
B O
and O
Sp1 O
were O
, O
therefore O
, O
analyzed O
in O
isolated O
T B
cells I
and O
DCs B
from O
humans O
and O
mice O
. O

T B
cells I
lack O
active O
NF-kappa O
B O
but O
express O
Sp1 O
as O
expected O
. O

DCs B
express O
high O
levels O
of O
all O
known O
NF-kappa O
B O
and O
Rel O
proteins O
, O
with O
activity O
residing O
primarily O
within O
RelB O
, O
p50 O
, O
and O
p65 O
. O

However O
, O
DCs B
lack O
Sp1 O
, O
which O
may O
explain O
the O
failure O
of O
HIV-1 O
to O
replicate O
in O
purified O
DCs B
. O

Coexpression O
of O
NF-kappa O
B O
and O
Sp1 O
occurs O
in O
the O
heterologous B
DC-T-cell I
syncytia I
that O
are O
induced O
by O
HIV-1 O
. O

Since O
DCs B
and O
memory O
T B
cells I
frequently O
traffic O
together O
in O
situ O
, O
these O
unusual O
heterologous B
syncytia I
could O
develop O
in O
infected O
individuals O
and O
lead O
to O
chronic O
HIV-1 O
replication O
without O
ostensible O
immune O
stimulation O
. O

Cloning O
a O
cDNA O
from O
human O
NK/T B
cells I
which O
codes O
for O
a O
protein O
with O
high O
proline O
content O
. O

A O
polyclonal O
antiserum O
raised O
against O
recombinant O
B4-2 O
recognizes O
a O
32-34 O
kDa O
protein O
in O
lymphocytes B
. O

The O
present O
study O
verified O
the O
ability O
of O
IL-2 O
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 O
and O
JAK3 O
, O
but O
demonstrated O
that O
IL-2 O
stimulated O
JAK3 O
to O
a O
significantly O
larger O
extent O
than O
JAK1 O
in O
human B
T I
lymphocytes I
and O
the O
YT O
cell O
line O
. O

Moreover O
, O
STAT5 O
was O
found O
to O
be O
the O
predominant O
STAT O
transcription O
factor O
used O
by O
IL-2 O
in O
human B
T I
cells I
, O
and O
specifically O
required O
a O
COOH-terminal O
region O
of O
IL-2R O
beta O
( O
Ser386-Val525 O
) O
, O
while O
STAT5 O
recruitment O
was O
not O
correlated O
to O
activation O
of O
IL-2R O
gamma O
or O
JAK3 O
. O

Up-regulation O
of O
high-affinity O
dehydroepiandrosterone O
binding O
activity O
by O
dehydroepiandrosterone O
in O
activated O
human B
T I
lymphocytes I
. O

These O
results O
not O
only O
indicate O
the O
existence O
of O
a O
DHEA O
receptor O
, O
but O
also O
suggest O
that O
T B
cells I
become O
susceptible O
to O
regulation O
by O
DHEA O
during O
the O
process O
of O
signal-induced O
activation O
. O

In O
addition O
, O
the O
concentration O
of O
androgen O
receptors O
in O
mononuclear B
leukocytes I
was O
measured O
, O
in O
both O
the O
follicular O
and O
luteal O
phases O
of O
the O
menstrual O
cycle O
, O
basally O
and O
after O
4 O
months O
of O
flutamide O
treatment O
. O

A O
variety O
of O
other O
cells O
, O
including O
transformed B
erythroid I
precursors I
, O
do O
not O
have O
IBR O
but O
a O
factor O
referred O
to O
as O
IBF O
( O
68 O
to O
70 O
kDa O
) O
that O
recognizes O
the O
same O
IBR O
sites O
. O

We O
investigated O
the O
molecular O
basis O
of O
the O
synergistic O
induction O
by O
interferon-gamma O
( O
IFN-gamma O
) O
/ O
tumor O
necrosis O
factor-alpha O
( O
TNF-alpha O
) O
of O
human O
interleukin-6 O
( O
IL-6 O
) O
gene O
in O
THP-1 B
monocytic I
cells I
, O
and O
compared O
it O
with O
the O
basis O
of O
this O
induction O
by O
lipopolysaccharide O
( O
LPS O
) O
. O

Synergistic O
induction O
of O
the O
IL-6 O
gene O
by O
IFN-gamma O
and O
TNF-alpha O
, O
in O
monocytic B
cells I
, O
involved O
cooperation O
between O
the O
IRF-1 O
and O
NF O
kappa O
B O
p65 O
homodimers O
with O
concomitant O
removal O
of O
the O
negative O
effect O
of O
the O
retinoblastoma O
control O
element O
present O
in O
the O
IL-6 O
promoter O
. O

An O
Epstein-Barr O
virus O
( O
EBV O
) O
-transformed O
cell O
line O
derived O
from O
her O
lymphocytes B
had O
normal O
gamma O
c O
expression O
but O
lacked O
Jak3 O
protein O
and O
had O
greatly O
diminished O
Jak3 O
messenger O
RNA O
. O

Constitutive O
overexpression O
of O
the O
L-selectin O
gene O
in O
fresh O
leukemic B
cells I
of O
adult O
T-cell O
leukemia O
that O
can O
be O
transactivated O
by O
human O
T-cell O
lymphotropic O
virus O
type O
1 O
Tax O
. O

To O
understand O
the O
mechanism O
of O
leukemic B
cell I
infiltration O
into O
organs O
, O
we O
studied O
the O
expression O
and O
regulation O
of O
L-selectin O
mRNA O
in O
fresh O
leukemic B
cells I
of O
adult O
T-cell O
leukemia O
( O
ATL O
) O
patients O
and O
investigated O
the O
response O
of O
the O
L-selectin O
promoter O
to O
human O
T-cell O
lymphotropic O
virus O
type O
1 O
( O
HTLV-1 O
) O
Tax O
, O
which O
is O
a O
viral O
transcriptional O
transactivator O
. O

Studies O
using O
in O
situ O
hybridization O
showed O
expression O
of O
the O
L-selectin O
mRNA O
in O
the O
infiltrating O
leukemic B
cells I
in O
the O
liver O
of O
two O
ATL O
patients O
. O

The O
only O
exception O
is O
represented O
by O
the O
P3HR1 O
cells O
, O
in O
which O
, O
however O
, O
the O
infection O
by O
the O
variant O
B O
does O
not O
determine O
induction O
of O
EBV O
antigens O
; O
( O
2 O
) O
the O
presence O
of O
the O
EBV O
genome O
contributes O
to O
the O
susceptibility O
of O
the O
B O
cell O
lines O
to O
HHV-6 O
infection O
, O
increasing O
the O
binding O
sites O
and O
the O
percentage O
of O
infectable B
cells I
, O
as O
detected O
by O
immunoelectron O
microscopy O
; O
and O
( O
3 O
) O
HHV-6 O
infected O
T O
cells O
, O
transfected O
with O
plasmids O
bearing O
the O
promoter O
regions O
of O
the O
EBV O
early O
genes O
BZLF1 O
and O
BMRF1 O
, O
show O
a O
strong O
transactivation O
of O
these O
promoters O
. O

Although O
the O
expression O
of O
CD69 O
can O
be O
induced O
in O
vitro O
on O
cells O
of O
most O
hematopoietic O
lineages O
with O
a O
wide O
variety O
of O
stimuli O
, O
in O
vivo O
it O
is O
mainly O
expressed O
by O
T-lymphocytes B
located O
in O
the O
inflammatory O
infiltrates O
of O
several O
human O
diseases O
. O

To O
elucidate O
the O
mechanisms O
that O
regulate O
the O
constitutive O
and O
inducible O
expression O
of O
CD69 O
by O
leukocytes B
, O
we O
isolated O
the O
promoter O
region O
of O
the O
CD69 O
gene O
and O
carried O
out O
its O
functional O
characterization O
. O

Organizational O
analysis O
and O
mapping O
of O
protein O
kinase O
C O
-- O
responsive O
elements O
regulating O
expression O
in O
platelets B
. O

These O
findings O
strongly O
suggest O
that O
the O
mechanism O
for O
previously O
described O
upregulation O
of O
platelet O
thromboxane O
receptors O
after O
acute O
myocardial O
infarction O
is O
increased O
thromboxane O
receptor O
gene O
transcription O
in O
platelet-progenitor B
cells I
. O

If O
, O
as O
the O
literature O
suggests O
, O
NK O
activity O
is O
relevant O
to O
breast O
cancer O
control O
, O
and O
since O
ER O
-tumors O
have O
a O
worse O
prognosis O
, O
we O
suggest O
here O
that O
perhaps O
such O
tumors O
are O
resistant O
to O
control O
by O
NK B
cells I
because O
they O
lack O
the O
ability O
to O
attract O
an O
accumulation O
of O
effector B
cells I
to O
the O
tumor O
site O
, O
or O
because O
blocking O
factors O
at O
the O
site O
of O
the O
tumor O
prevent O
local O
tumor O
control O
at O
the O
site O
of O
action O
. O

Nuclear O
factor-IL6 O
activates O
the O
human O
IL-4 O
promoter O
in O
T B
cells I
. O

Our O
results O
demonstrate O
that O
NF-IL6 O
is O
involved O
in O
transcriptional O
activation O
of O
the O
human O
IL-4 O
promoter O
in O
T B
cells I
. O

The O
TCF-1 O
protein O
was O
detectable O
in O
all O
samples O
of O
a O
set O
of O
22 O
T-cell B
malignancies I
of O
various O
stages O
of O
maturation O
, O
but O
was O
absent O
from O
a O
large O
number O
of O
other O
hematologic B
neoplasms I
. O

Cross-linking O
of O
Fc O
gamma O
receptors O
activates O
HIV-1 O
long O
terminal O
repeat O
-driven O
transcription O
in O
human B
monocytes I
. O

Here O
we O
report O
that O
cross-linking O
of O
Fc O
gamma O
RI O
or O
Fc O
gamma O
RII O
by O
adherent O
human O
IgG O
or O
by O
specific O
anti-Fc O
gamma O
R O
mAb O
activates O
HIV-1 O
gene O
expression O
in O
the O
human O
monocytic O
cell O
line O
BF24 O
and O
increased O
HIV O
RNA O
expression O
in O
monocytes B
from O
HIV O
infected O
patients O
as O
assayed O
by O
reverse O
transcription-PCR O
. O

These O
results O
indicate O
that O
Fc O
gamma O
R O
can O
mediate O
a O
TNF-alpha O
-dependent O
induction O
of O
HIV-1 O
gene O
transcription O
and O
suggest O
that O
immune O
complexes O
may O
contribute O
to O
the O
pathophysiology O
of O
HIV-1 O
infection O
by O
augmenting O
viral O
replication O
in O
monocytes B
. O

To O
compare O
the O
role O
of O
CD28 O
, O
neonatal B
and O
adult B
T I
cells I
were O
stimulated O
with O
a O
pair O
of O
mitogenic O
anti-CD2 O
antibodies O
in O
the O
presence O
or O
absence O
of O
anti-CD28 O
MoAb O
. O

With O
anti-CD2 O
alone O
, O
neonatal B
T I
cells I
proliferated O
slightly O
but O
produced O
no O
detectable O
IL-2 O
, O
whereas O
adult O
T B
cells I
proliferated O
vigorously O
, O
with O
significant O
IL-2 O
production O
. O

Costimulation O
with O
anti-CD28 O
MoAb O
greatly O
enhanced O
the O
proliferative O
response O
of O
neonatal B
T I
cells I
to O
levels O
equivalent O
to O
those O
of O
adult B
T I
cells I
, O
whereas O
adult B
T I
cells I
showed O
only O
slight O
increases O
. O

Although O
IL-2 O
secretion O
was O
increased O
in O
the O
presence O
of O
anti-CD28 O
MoAb O
, O
neonatal B
T I
cell I
IL-2 O
production O
remained O
lower O
than O
in O
adults O
. O

The O
cellular O
mechanism O
governing O
the O
diminished O
proliferative O
response O
of O
neonatal B
T I
lymphocytes I
to O
anti-CD2 O
may O
therefore O
be O
due O
to O
decreased O
NF O
kappa O
B O
induction O
, O
reduced O
IL-2 O
mRNA O
expression O
and O
deficient O
IL-2 O
production O
. O

TCL1 O
oncogene O
activation O
in O
preleukemic B
T I
cells I
from O
a O
case O
of O
ataxia-telangiectasia O
. O

Similar O
chromosomal O
rearrangements O
occur O
also O
in O
the O
clonally O
expanded O
T B
cells I
in O
AT O
patients O
before O
the O
appearance O
of O
the O
overt O
leukemia O
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 O
mRNA O
and O
protein O
in O
peripheral B
blood I
lymphocytes I
( O
PBLs B
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

We O
found O
that O
the O
TCL1 O
gene O
was O
overexpressed O
in O
the O
PBLs B
of O
an O
AT O
patient O
with O
a O
large O
clonal O
T-cell O
population O
exhibiting O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
but O
not O
in O
the O
lymphocytes B
of O
the O
other O
cases O
. O

C/EBP O
proteins O
activate O
transcription O
from O
the O
human O
immunodeficiency O
virus O
type O
1 O
long O
terminal O
repeat O
in O
macrophages/ O
monocytes B
. O

We O
have O
determined O
the O
functional O
role O
of O
C/EBP O
proteins O
and O
C/EBP O
sites O
in O
regulating O
transcription O
from O
the O
HIV- O
1 O
LTR O
in O
monocytes/macrophages B
. O

Human O
immunodeficiency O
virus O
type-2 O
gene O
expression O
: O
two O
enhancers O
and O
their O
activation O
by O
T-cell B
activators O
. O

We O
have O
shown O
earlier O
that O
NF-M O
, O
the O
chicken O
homolog O
of O
C/EBP O
beta O
, O
is O
specifically O
expressed O
in O
myelomonocytic B
and I
eosinophilic I
cells I
of O
the O
hematopoietic O
system O
. O

At O
the O
same O
time O
, O
we O
observed O
a O
down-regulation O
of O
progenitor-specific O
surface O
markers O
and O
the O
up-regulation O
of O
differentiation O
markers O
restricted O
to O
the O
eosinophil B
and O
myeloid B
lineages I
. O

Our O
results O
suggest O
that O
NF-M O
plays O
an O
important O
role O
in O
commitment O
along O
the O
eosinophil B
lineage I
and O
in O
the O
induction O
of O
apoptosis O
. O

Prolactin O
and O
interleukin-2 O
receptors O
in O
T B
lymphocytes I
signal O
through O
a O
MGF-STAT5-like O
transcription O
factor O
. O

The O
cell O
surface O
receptors O
for O
PRL O
and O
interleukin-2 O
( O
IL-2 O
) O
are O
structurally O
distinct O
, O
but O
share O
regulatory O
tasks O
in O
T B
lymphocytes I
. O

They O
can O
stimulate O
proliferation O
and O
activate O
transcription O
of O
over-lapping O
sets O
of O
genes O
of O
T B
cells I
. O

Activation O
of O
T B
helper I
cells I
results O
in O
coordinate O
expression O
of O
a O
number O
of O
cytokines O
involved O
in O
differentiation O
, O
proliferation O
and O
activation O
of O
the O
haematopoietic O
system O
. O

A O
number O
of O
the O
ETS O
family O
of O
transcription O
factors O
are O
expressed O
in O
T B
cells I
, O
including O
ETS1 O
and O
ELF1 O
. O

Together O
these O
data O
suggest O
that O
ETS1 O
may O
be O
involved O
in O
mediating O
the O
increased O
GM-CSF O
production O
associated O
with O
T B
cell I
activation O
. O

Total O
RNA O
was O
isolated O
from O
peripheral B
blood I
mononuclear I
cells I
and O
hTR O
beta O
1 O
mRNA O
levels O
determined O
by O
quantitative O
competitive O
reverse O
transcription O
PCR O
. O

For O
comparison O
, O
hTR O
beta O
1 O
mRNA O
levels O
were O
determined O
in O
lymphocytes B
and O
normal O
thyroid O
tissue O
of O
euthyroid O
patients O
. O

Human O
TR O
beta O
1 O
mRNA O
levels O
in O
lymphocytes B
were O
1.8 O
+/- O
0.4 O
, O
1.9 O
+/- O
0.5 O
, O
1.1 O
+/- O
0.4 O
10 O
( O
-18 O
) O
mol/microgram O
RNA O
in O
hypo- O
, O
eu O
-and O
hyperthyroid O
patients O
, O
respectively O
, O
corresponding O
to O
an O
estimated O
0.5 O
-2 O
molecules O
per O
cell O
. O

Absolute O
hTR O
beta O
1 O
mRNA O
levels O
are O
very O
low O
with O
an O
estimated O
one O
molecule O
of O
mRNA O
being O
present O
in O
a O
mononuclear B
blood I
cell I
or O
thyrocyte B
. O

PU.1 O
seems O
to O
be O
required O
for O
early O
development O
of O
multiple B
hematopoietic I
lineages I
, O
but O
its O
expression O
in O
mature B
cells I
is O
preferentially O
observed O
in O
cells O
of O
the O
B-cell-and B
monocyte/macrophage-differentiation I
lineage I
. O

It O
binds O
the O
so-called O
Pu O
box O
, O
an O
important O
tissue-specific O
regulatory O
DNA O
element O
present O
in O
a O
number O
of O
genes O
expressed O
in O
these O
cell B
lineages I
. O

In O
contrast O
, O
in O
a O
number O
of O
multiple O
myeloma O
cell O
lines O
, O
representing O
differentiated B
, I
plasma I
cell-like I
B I
cells I
, O
PU.1 O
DNA O
binding O
activity O
, O
mRNA O
expression O
, O
and O
Pu O
box O
-dependent O
transactivation O
were O
absent O
or O
detectable O
at O
a O
very O
low O
level O
. O

The O
findings O
in O
the O
human O
multiple O
myeloma O
cell O
lines O
represent O
the O
first O
examples O
of O
B B
cells I
with O
downregulated O
PU.1 O
expression O
and O
apparently O
contradict O
observations O
in O
the O
murine O
system O
in O
which O
PU.1 O
is O
expressed O
and O
active O
in O
plasmacytoma O
cell O
lines O
. O

At O
present O
, O
it O
is O
unclear O
whether O
the O
lack O
of O
PU.1 O
expression O
and O
activity O
in O
human O
multiple O
myeloma O
cell O
lines O
represents O
a O
malignancy-associated O
defect O
in O
these O
cells O
or O
exemplifies O
a O
normal O
developmental O
regulation O
in O
terminally B
differentiated I
B I
cells I
. O

Regulation O
of O
granulocyte-macrophage O
colony-stimulating O
factor O
and O
E-selectin O
expression O
in O
endothelial B
cells I
by O
cyclosporin O
A O
and O
the O
T-cell O
transcription O
factor O
NFAT O
. O

As O
we O
observed O
that O
activated B
endothelial I
cells I
also O
expressed O
NFAT O
, O
we O
tested O
the O
antiinflammatory O
properties O
of O
CsA O
in O
endothelial B
cells I
. O

Significantly O
, O
CsA O
completely O
suppressed O
the O
induction O
of O
NFAT O
in O
endothelial B
cells I
and O
inhibited O
the O
activity O
of O
granulocyte-macrophage O
colony-stimulating O
factor O
( O
GM-CSF O
) O
gene O
regulatory O
elements O
that O
use O
NFAT O
by O
60 O
% O
. O

CsA O
similarly O
mediated O
a O
reduction O
of O
up O
to O
65 O
% O
in O
GM-CSF O
mRNA O
and O
protein O
expression O
in O
activated B
endothelial I
cells I
. O

Hence O
, O
induction O
of O
cell O
surface O
expression O
of O
this O
leukocyte O
adhesion O
molecule O
by O
tumor O
necrosis O
factor O
( O
TNF O
) O
-alpha O
was O
reduced O
by O
40 O
% O
in O
the O
presence O
of O
CsA O
, O
and O
this O
was O
reflected O
by O
a O
29 O
% O
decrease O
in O
neutrophil B
adhesion O
. O

The O
effects O
of O
CsA O
on O
endothelial B
cells I
were O
also O
detected O
at O
the O
chromatin O
structure O
level O
, O
as O
DNasel O
hypersensitive O
sites O
within O
both O
the O
GM-CSF O
enhancer O
and O
the O
E-selectin O
promoter O
were O
suppressed O
by O
CsA O
. O

This O
represents O
the O
first O
report O
of O
NFAT O
in O
endothelial B
cells I
and O
suggests O
mechanisms O
by O
which O
CsA O
could O
function O
as O
an O
antiinflammatory O
agent O
. O

Costimulation O
requirement O
for O
AP-1 O
and O
NF-kappa O
B O
transcription O
factor O
activation O
in O
T B
cells I
. O

The O
transcriptional O
activity O
of O
the O
IL-2 O
promoter O
requires O
T-cell B
costimulation O
delivered O
by O
the O
TCR O
and O
the O
auxiliary O
receptor O
CD28 O
. O

Furthermore O
, O
in O
activated B
T I
cells I
, O
the O
kinetics O
of O
the O
two O
phosphorylation O
events O
are O
essentially O
similar O
. O

Regulation O
of O
human O
immunodeficiency O
virus O
type O
1 O
and O
cytokine O
gene O
expression O
in O
myeloid B
cells I
by O
NF-kappa O
B/Rel O
transcription O
factors O
. O

CD4+ O
macrophages O
in O
tissues O
such O
as O
lung O
, O
skin O
, O
and O
lymph O
nodes O
, O
promyelocytic B
cells I
in O
bone O
marrow O
, O
and O
peripheral B
blood I
monocytes I
serve O
as O
important O
targets O
and O
reservoirs O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV-1 O
) O
replication O
. O

HIV-1-infected O
myeloid B
cells I
are O
often O
diminished O
in O
their O
ability O
to O
participate O
in O
chemotaxis O
, O
phagocytosis O
, O
and O
intracellular O
killing O
. O

HIV-1 O
infection O
of O
myeloid B
cells I
can O
lead O
to O
the O
expression O
of O
surface O
receptors O
associated O
with O
cellular O
activation O
and/or O
differentiation O
that O
increase O
the O
responsiveness O
of O
these O
cells O
to O
cytokines O
secreted O
by O
neighboring O
cells O
as O
well O
as O
to O
bacteria O
or O
other O
pathogens O
. O

Chronic O
HIV-1 O
infection O
of O
myeloid B
cells I
leads O
to O
constitutive O
NF-kappa O
B O
DNA-binding O
activity O
and O
provides O
an O
intranuclear O
environment O
capable O
of O
perpetuating O
HIV-1 O
replication O
. O

In O
response O
to O
secondary O
pathogenic O
infections O
or O
antigenic O
challenge O
, O
cytokine O
gene O
expression O
is O
rapidly O
induced O
, O
enhanced O
, O
and O
sustained O
over O
prolonged O
periods O
in O
HIV-1-infected O
myeloid O
cells O
compared O
with O
uninfected B
cells I
. O

Steroid O
mediated O
lysis O
of O
lymphoblasts B
requires O
the O
DNA O
binding O
region O
of O
the O
steroid O
hormone O
receptor O
. O

Glucocorticoids O
kill O
certain O
types O
of O
lymphoblasts B
, O
but O
the O
mechanisms O
are O
unknown O
. O

In O
this O
report O
we O
have O
asked O
which O
region O
( O
s O
) O
of O
the O
steroid O
receptor O
are O
important O
for O
mediating O
lysis O
in O
leukemic B
T I
lymphoblasts I
. O

One O
such O
cofactor O
, O
BOB.1/OBF.1 O
, O
was O
recently O
isolated O
from O
human B
B I
cells I
. O

BOB.1/OBF.1 O
can O
efficiently O
activate O
octamer-dependent O
promoters O
in O
fibroblasts B
; O
however O
, O
it O
fails O
to O
stimulate O
octamer-dependent O
enhancer O
activity O
. O

Consistent O
with O
the O
failure O
of O
full-length O
BOB.1/OBF.1 O
to O
stimulate O
octamer-dependent O
enhancer O
elements O
in O
non B
B I
cells I
, O
the O
GAL4 O
fusions O
likewise O
only O
stimulate O
from O
a O
promoter-proximal O
position O
. O

Anti-immunoglobulin O
M O
activates O
nuclear O
calcium/calmodulin-dependent O
protein O
kinase O
II O
in O
human B
B I
lymphocytes I
. O

We O
and O
others O
have O
previously O
shown O
that O
the O
nuclear O
protein O
, O
Ets-1 O
, O
is O
phosphorylated O
in O
a O
calcium-dependent O
manner O
after O
ligation O
of O
immunoglobulin O
( O
Ig O
) O
M O
on O
B B
lymphocytes I
. O

These O
data O
suggest O
a O
model O
of O
signal O
transduction O
by O
the O
antigen O
receptor O
on O
B B
lymphocytes I
in O
which O
increased O
intracellular O
free O
calcium O
can O
rapidly O
activate O
nuclear O
CaM O
kinase O
II O
, O
potentially O
resulting O
in O
phosphorylation O
and O
regulation O
of O
DNA-binding O
proteins O
. O

However O
, O
activation O
from O
a O
remote O
position O
could O
only O
be O
achieved O
with O
the O
C-terminus O
of O
Oct-2a O
in O
B B
cells I
. O

In O
lymphoid B
cells I
, O
higher O
activation O
levels O
were O
observed O
, O
suggesting O
that O
distinct O
B-cell-specific O
cofactors O
in O
concert O
with O
the O
effector O
domains O
of O
Oct-2a O
might O
be O
involved O
in O
mediating O
transcription O
from O
proximal O
and O
remote O
positions O
. O

Nonopsonic O
phagocytosis O
of O
Pseudomonas O
aeruginosa O
by O
macrophages B
and O
polymorphonuclear B
leukocytes I
requires O
the O
presence O
of O
the O
bacterial O
flagellum O
. O

The O
RpoN O
mutant O
, O
lacking O
pili O
, O
flagella O
, O
and O
nonpilus O
adhesins O
, O
bound O
poorly O
and O
was O
resistant O
to O
ingestion O
by O
both O
macrophages B
and O
neutrophils B
. O

The O
presence O
of O
a O
flagellum O
was O
not O
required O
for O
binding O
of O
P. O
aeruginosa O
to O
macrophages B
but O
was O
critical O
for O
the O
subsequent O
internalization O
of O
the O
bacterium O
, O
suggesting O
that O
this O
factor O
or O
a O
surface O
ligand O
associated O
with O
its O
assembly O
was O
responsible O
for O
stimulation O
of O
nonopsonic O
phagocytosis O
. O

The O
congenital O
absence O
of O
the O
receptor O
results O
in O
a O
bleeding O
disorder O
associated O
with O
`` B
giant I
'' I
platelets I
, O
a O
condition O
linking O
the O
expression O
of O
the O
complex O
to O
platelet O
morphogenesis O
. O

GP O
Ib O
alpha O
promoter O
activity O
was O
evaluated O
by O
transfection O
of O
human B
erythroleukemia I
cells I
with O
reporter O
plasmids O
coding O
for O
the O
enzyme O
, O
luciferase O
. O

Studies O
were O
initiated O
with O
a O
fragment O
extending O
2 O
, O
738 O
nucleotides O
5 O
' O
to O
the O
transcription O
start O
site O
and O
lead O
to O
the O
identification O
of O
253 O
nucleotides O
retaining O
full O
promoter O
activity O
in O
human B
erythroleukemia I
cells I
. O

In O
cells O
of O
nonhematopoietic B
lineage I
, O
human B
endothelial I
and O
HeLa B
cells I
, O
the O
GP O
Ib O
alpha O
promoter O
activity O
was O
no O
greater O
than O
background O
levels O
obtained O
with O
promoterless O
constructs O
. O

The O
results O
define O
essential O
cis-acting O
elements O
responsible O
for O
the O
expression O
of O
GP O
Ib O
alpha O
and O
provide O
insights O
into O
molecular O
events O
coinciding O
with O
the O
release O
of O
normal B
platelets I
into O
the O
bloodstream O
. O

The O
trapped O
LDL O
is O
seeded O
with O
oxidative O
species O
released O
by O
the O
overlying O
endothelium O
, O
and O
lipid O
oxidation O
is O
initiated O
within O
the O
LDL O
particle. O
Some O
of O
the O
lipids O
that O
result O
lead O
to O
the O
activation O
of O
NFkB-like O
transcription O
factors O
that O
cause O
the O
expression O
of O
genes O
whose O
protein O
products O
mediate O
monocyte O
binding O
, O
monocyte B
chemotaxis O
into O
the O
subendothelial O
space O
, O
and O
conversion O
into O
macrophages B
. O

Immunofluorescence O
colocalization O
of O
both O
estrogen O
and O
progesterone O
receptors O
with O
eosinophil O
cationic O
protein O
showed O
that O
approximately O
70 O
% O
of O
positive B
cells I
were O
eosinophils B
. O

CONCLUSIONS O
: O
Sexual O
hormones O
, O
through O
their O
receptors O
, O
may O
influence O
the O
activity O
of O
eosinophils B
in O
patients O
with O
VKC O
. O

It O
has O
long O
been O
a O
puzzle O
that O
MHC O
class O
II O
molecules O
are O
expressed O
in O
human B
T I
cells I
after O
activation O
but O
not O
in O
mouse B
T I
cells I
; O
this O
expression O
is O
believed O
to O
play O
a O
role O
in O
the O
cell O
mediated O
immune O
response O
. O

Here O
we O
show O
that O
human B
T I
cells I
expressing O
MHC O
class O
II O
have O
CIITA O
transcripts O
while O
MHC O
class O
II-negative O
human B
T I
cells I
and O
mouse B
T I
cells I
do O
not O
. O

The O
expression O
of O
MHC O
class O
II O
genes O
in O
mouse B
T I
cells I
can O
be O
reconstituted O
upon O
transfection O
with O
the O
human O
CIITA O
cDNA O
. O

These O
data O
indicate O
that O
the O
expression O
of O
CIITA O
explains O
the O
expression O
or O
lack O
of O
expression O
of O
MHC O
class O
II O
in O
human B
and O
mouse B
T I
cells I
respectively O
. O

Inhibition O
of O
NF-AT O
-dependent O
transcription O
by O
NF-kappa O
B O
: O
implications O
for O
differential O
gene O
expression O
in O
T B
helper I
cell I
subsets I
. O

We O
used O
mononuclear O
cell O
priming O
cultures O
and O
inflammatory B
synovial I
fluids I
( O
SFs B
) O
derived O
from O
arthritis O
patients O
to O
examine O
the O
regulation O
of O
cytokine O
production O
and O
STAT O
activity O
by O
an O
inflammatory O
synovial O
microenvironment O
. O

Exposure O
to O
SFs B
during O
priming O
resulted O
in O
an O
81 O
% O
inhibition O
of O
interferon O
( O
IFN O
) O
-gamma O
, O
but O
not O
interleukin O
( O
IL O
) O
4 O
, O
production O
by O
effector B
cells I
generated O
in O
priming O
cultures O
. O

SFs B
blocked O
the O
sustained O
activity O
of O
transcription O
factor O
Stat1 O
, O
but O
not O
Stat3 O
, O
during O
the O
priming O
period O
, O
and O
Stat1 O
activity O
was O
differentially O
regulated O
by O
cytokines O
in O
parallel O
with O
their O
positive O
or O
negative O
regulation O
of O
IFN-gamma O
production O
. O

These O
results O
suggest O
a O
role O
for O
altered O
balance O
of O
Stat1 O
and O
Stat3 O
transcriptional O
activity O
in O
the O
regulation O
of O
T B
cell I
differentiation O
and O
in O
the O
pathogenesis O
of O
inflammatory O
synovitis O
. O

Triggering O
of O
complement O
receptors O
CR1 O
( O
CD35 O
) O
and O
CR3 O
( O
CD11b/CD18 O
) O
induces O
nuclear O
translocation O
of O
NF-kappa O
B O
( O
p50/p65 O
) O
in O
human B
monocytes I
and O
enhances O
viral O
replication O
in O
HIV-infected B
monocytic I
cells I
. O

Monocyte/macrophages B
may O
harbor O
HIV O
in O
a O
nonproductive O
fashion O
for O
prolonged O
periods O
of O
time O
. O

We O
further O
observed O
that O
stimulation O
of O
CR1 O
or O
CR3 O
induces O
the O
nuclear O
translocation O
of O
NF-kappa O
B O
p50/p65 O
in O
infected B
cells I
. O

Translocation O
of O
NF-kappa O
B O
p50/p65 O
was O
also O
observed O
following O
stimulation O
of O
CR1 O
or O
CR3 O
of O
uninfected B
peripheral I
blood I
monocytes I
from O
HIV-seronegative O
donors O
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
HIV O
gene O
expression O
may O
be O
activated O
in O
infected B
monocytes I
through O
interaction O
of O
the O
cells O
with O
complement-opsonized O
particles O
and O
that O
enhanced O
viral O
replication O
is O
associated O
with O
C3 O
receptor O
-mediated O
nuclear O
translocation O
of O
the O
NF-kappa O
B O
complex O
. O

Attenuation O
of O
gamma O
interferon O
-induced O
tyrosine O
phosphorylation O
in O
mononuclear B
phagocytes I
infected O
with O
Leishmania O
donovani O
: O
selective O
inhibition O
of O
signaling O
through O
Janus O
kinases O
and O
Stat1 O
. O

The O
induction O
of O
gene O
transcription O
in O
response O
to O
gamma O
interferon O
is O
impaired O
in O
mononuclear B
phagocytes I
infected O
with O
Leishmania O
donovani O
, O
and O
the O
mechanisms O
involved O
are O
not O
fully O
understood O
. O

Increased O
labeling O
of O
these O
proteins O
occurred O
to O
similar O
extents O
in O
control B
cells I
and O
in O
cells O
that O
had O
been O
infected O
with O
L. O
donovani O
for O
16 O
h O
. O

Results O
similar O
to O
those O
observed O
with O
U-937 O
cells O
were O
also O
obtained O
with O
human B
peripheral I
blood I
monocytes I
. O

These O
findings O
indicate O
that O
infection O
of O
human B
mononuclear I
phagocytes I
with O
L. O
donovani O
leads O
to O
impaired O
gamma O
interferon O
-mediated O
tyrosine O
phosphorylation O
and O
selective O
effects O
on O
the O
Jak- O
Stat1 O
pathway O
. O

Unresponsiveness O
to O
gamma O
interferon O
for O
activation O
of O
this O
pathway O
may O
explain O
impaired O
transcriptional O
responses O
in O
leishmania-infected B
cells I
. O

Here O
, O
we O
demonstrate O
that O
the O
human O
GM-CSF O
receptor O
alpha O
promoter O
directs O
reporter O
gene O
activity O
in O
a O
tissue-specific O
fashion O
in O
myelomonocytic B
cells I
, O
which O
correlates O
with O
its O
expression O
pattern O
as O
analyzed O
by O
reverse O
transcription O
PCR O
. O

Point O
mutations O
of O
either O
the O
PU.1 O
site O
or O
the O
C/EBP O
site O
that O
abolish O
the O
binding O
of O
the O
respective O
factors O
result O
in O
a O
significant O
decrease O
of O
GM-CSF O
receptor O
alpha O
promoter O
activity O
in O
myelomonocytic B
cells I
only O
. O

The O
novel O
complex O
is O
distinct O
from O
that O
described O
previously O
as O
binding O
to O
B O
cell O
enhancer O
sites O
and O
can O
be O
formed O
by O
addition O
of O
PU.1 O
to O
extracts O
from O
certain O
nonmyeloid B
cell I
types I
which O
do O
not O
express O
PU.1 O
, O
including O
T B
cells I
and O
epithelial B
cells I
, O
but O
not O
from O
erythroid B
cells I
. O

Expression O
of O
PU.1 O
in O
nonmyeloid B
cells I
can O
activate O
the O
GM-CSF O
receptor O
alpha O
promoter O
. O

Finally O
, O
we O
demonstrate O
that O
C/EBP O
alpha O
can O
also O
active O
the O
GM-CSF O
receptor O
alpha O
promoter O
in O
nonmyeloid B
cells I
. O

A O
naturally O
occurring O
mutation O
( O
-175 O
T-C O
) O
in O
the O
area O
bound O
by O
HMG-I O
results O
in O
overexpression O
of O
gamma-globin O
in O
adult B
red I
blood I
cells I
( O
HPFH B
) O
and O
up-regulation O
of O
the O
gamma-globin O
promoter O
in O
in O
vitro O
expression O
assays O
; O
HMG-I O
does O
not O
bind O
to O
this O
mutant O
sequence O
. O

These O
findings O
implicate O
HMG-I O
in O
the O
HPFH B
phenotype O
; O
we O
speculate O
that O
it O
may O
participate O
in O
the O
formation O
of O
multiprotein O
complexes O
that O
regulate O
globin O
gene O
expression O
. O

Our O
previous O
data O
obtained O
from O
a O
tax O
transgenic O
mouse O
model O
revealed O
that O
tax O
transforms O
mouse B
fibroblasts I
but O
not O
thymocytes B
, O
despite O
comparable O
levels O
of O
tax O
expression O
in O
both O
tissues O
. O

Constitutive O
tyrosine O
phosphorylation O
of O
a O
130-kD O
protein O
( O
s O
) O
was O
observed O
in O
the O
tax O
transformed O
fibroblast O
B O
line O
and O
in O
HTLV-1 O
transformed O
human O
lymphoid O
lines O
, O
but O
not O
in O
thymocytes B
from O
Thy-tax O
transgenic O
mice O
. O

Constitutive O
phosphorylation O
of O
Jak O
kinases O
may O
facilitate O
tumor O
growth O
in O
both O
HTLV-1 B
infected I
human I
T I
cells I
and O
the O
transgenic O
mouse O
model O
. O

Application O
of O
a O
`` O
formamide O
free O
'' O
and O
thus O
`` O
material O
preserving O
'' O
in O
situ O
hybridization O
technique O
using O
the O
cDNA O
of O
the O
myf3 O
gene O
revealed O
the O
following O
results O
: O
Human B
rhabdomyosarcoma I
cells I
, O
characterized O
by O
a O
high O
expression O
of O
myf3 O
show O
intensive O
hybridization O
signals O
in O
their O
interphase O
. O

In O
comparison O
, O
isolated O
nuclei O
of O
human B
lymphocytes I
in O
which O
no O
need O
for O
the O
expression O
of O
this O
gene O
exists O
, O
show O
barely O
hybridization O
signals O
. O

Oncogenicity O
of O
human O
papillomavirus- O
or O
adenovirus-transformed O
cells O
correlates O
with O
resistance O
to O
lysis O
by O
natural B
killer I
cells I
. O

The O
reasons O
for O
the O
dissimilar O
oncogenicities O
of O
human O
adenoviruses O
and O
human O
papillomaviruses O
( O
HPV O
) O
in O
humans O
are O
unknown O
but O
may O
relate O
to O
differences O
in O
the O
capacities O
of O
the O
E1A O
and O
E7 O
proteins O
to O
target B
cells I
for O
rejection O
by O
the O
host B
natural I
killer I
( I
NK I
) I
cell I
response O
. O

As O
one O
test O
of O
this O
hypothesis O
, O
we O
compared O
the O
abilities O
of O
E1A O
-and O
E7 O
-expressing O
human O
fibroblastic O
or O
keratinocyte-derived O
human O
cells O
to O
be O
selectively O
killed O
by O
either O
unstimulated B
or O
interferon O
( O
IFN O
) O
-activated O
NK O
cells O
. O

Cells O
expressing O
the O
E1A O
oncoprotein O
were O
selectively O
killed O
by O
unstimulated O
NK O
cells O
, O
while O
the O
same O
parental B
cells I
but O
expressing O
the O
HPV O
type O
16 O
( O
HPV-16 O
) O
or O
HPV-18 O
E7 O
oncoprotein O
were O
resistant O
to O
NK O
cell O
lysis O
. O

The O
extent O
of O
IFN O
-induced O
NK O
cell O
killing O
of O
E1A-expressing O
cells O
was O
proportional O
to O
the O
level O
of O
E1A O
expression O
and O
correlated O
with O
the O
ability O
of O
E1A O
to O
block O
IFN O
-stimulated O
gene O
expression O
in O
target B
cells I
. O

In O
conclusion O
, O
E1A O
expression O
marks O
cells O
for O
destruction O
by O
the O
host O
NK B
cell I
response O
, O
whereas O
the O
E7 O
oncoprotein O
lacks O
this O
activity O
. O

Treatment O
of O
T B
cells I
with O
the O
selective O
PKC O
inhibitor O
GF109203X O
abrogates O
the O
PMA-induced O
IkB O
alpha O
phosphorylation/degradation O
irrespective O
of O
activation O
of O
Ca O
( O
2+ O
) O
-dependent O
pathways O
, O
but O
not O
the O
phosphorylation O
and O
degradation O
of O
IkB O
alpha O
induced O
by O
TNF-alpha O
, O
a O
PKC O
-independent O
stimulus O
. O

Tissue-specific O
regulation O
of O
the O
rabbit O
15-lipoxygenase O
gene O
in O
erythroid B
cells I
by O
a O
transcriptional O
silencer O
. O

The O
15-lipoxygenase O
( O
lox O
) O
gene O
is O
expressed O
in O
a O
tissue-specific O
manner O
, O
predominantly O
in O
erythroid B
cells I
but O
also O
in O
airway B
epithelial I
cells I
and O
eosinophils B
. O

The O
main O
activity O
of O
the O
silencer O
has O
been O
mapped O
to O
the O
first O
900 O
bp O
of O
5 O
' O
flanking O
DNA O
, O
which O
contains O
nine O
binding O
sites O
for O
a O
nuclear O
factor O
present O
in O
non- O
erythroid B
cells I
but O
not O
in O
erythroid B
cells I
. O

Phosphorylation O
of O
the O
transcription O
factor O
NFATp O
inhibits O
its O
DNA O
binding O
activity O
in O
cyclosporin O
A-treated O
human O
B O
and O
T B
cells I
. O

Cyclosporin O
A O
( O
CsA O
) O
exerts O
its O
immunosuppressive O
effect O
by O
inhibiting O
the O
activity O
of O
nuclear O
factor O
of O
activated O
T B
cells I
( O
NFAT O
) O
, O
thus O
preventing O
transcriptional O
induction O
of O
several O
cytokine O
genes O
. O

We O
previously O
have O
demonstrated O
a O
requirement O
for O
oxidative O
events O
during O
cell O
cycle O
entry O
in O
T B
lymphocytes I
and O
have O
hypothesised O
that O
reactive O
oxygen O
species O
may O
act O
as O
intracellular O
signalling O
agents O
during O
lymphocyte O
activation O
. O

Treatment O
of O
normal O
human B
peripheral I
blood I
lymphocytes I
with O
cysteamine O
in O
vitro O
was O
found O
to O
inhibit O
proliferation O
in O
a O
dose-dependent O
manner O
, O
with O
essentially O
complete O
inhibition O
occurring O
at O
a O
dose O
of O
400 O
microM O
. O

The O
inhibitory O
effect O
of O
cysteamine O
may O
be O
mediated O
at O
least O
in O
part O
by O
an O
effect O
on O
transcription O
factor O
function O
, O
as O
the O
DNA O
binding O
activities O
of O
AP-1 O
and O
NF-kappa O
B O
extracted O
from O
mitogen-stimulated B
cells I
were O
significantly O
inhibited O
by O
cysteamine O
treatment O
. O

The O
identification O
of O
regulatory O
proteins O
, O
such O
as O
transcription O
factors O
, O
as O
molecular O
targets O
for O
oxidative O
signalling O
provides O
further O
evidence O
to O
implicate O
oxidative O
signalling O
as O
being O
intimately O
involved O
in O
the O
G0 O
to O
G1 O
phase O
transition O
in O
T B
lymphocytes I
. O

Sex O
and O
age O
distribution O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptors O
in O
peripheral B
blood I
mononuclear I
cells I
from O
normal O
human O
subjects O
. O

Specific O
receptors O
for O
1 O
, O
25 O
Dihydroxyvitamin O
D3 O
have O
been O
described O
in O
human O
peripheral B
blood I
mononuclear I
cells I
( O
PBMC B
) O
. O

The O
mean O
dissociation O
constant O
( O
Kd O
) O
was O
similar O
in O
both O
sexes O
( O
1.35 O
+/- O
0.70 O
x O
10 O
( O
-10 O
) O
M O
in O
males O
, O
1.13 O
+/- O
0.66 O
x O
10 O
( O
-10 O
) O
M O
in O
females O
) O
, O
but O
the O
concentration O
of O
binding O
sites O
( O
Nmax O
) O
was O
significantly O
lower O
in O
females O
( O
2.32 O
+/- O
0.92 O
fmol/10 O
( O
7 O
) O
PBMC B
vs O
4.43 O
+/- O
1.38 O
fmol/10 O
( O
7 O
) O
PBMC B
in O
males O
; O
p O
= O
0.0001 O
) O
. O

Expression O
of O
Id2 O
and O
Id3 O
mRNA O
in O
human B
lymphocytes I
. O

We O
examined O
by O
northern O
hybridization O
the O
expression O
of O
Id2 O
and O
Id3 O
mRNA O
in O
human O
leukemia/lymphoma O
lines O
and O
patient O
samples O
, O
as O
well O
as O
resting O
and O
activated O
normal O
human O
lymphocytes O
from O
peripheral O
blood O
( O
PBL B
) O
. O

In O
addition O
, O
resting B
PBL I
constitutively O
expressed O
prominent O
levels O
of O
Id2 O
mRNA O
, O
but O
not O
Id3 O
mRNA O
. O

Taken O
together O
, O
our O
studies O
revealed O
three O
unexpected O
findings O
which O
require O
further O
analysis O
: O
( O
1 O
) O
expression O
of O
Id2 O
mRNA O
is O
often O
associated O
with O
lymphocytic O
transformation O
by O
HTLV-I O
or O
-II O
; O
( O
2 O
) O
T-cells O
usually O
express O
either O
Id2 O
or O
Id3 O
mRNA O
, O
but O
B-cells O
often O
express O
both O
simultaneously O
; O
( O
3 O
) O
non-dividing O
, O
normal O
PBL B
express O
high O
levels O
of O
Id2 O
and O
no O
Id3 O
mRNA O
; O
and O
with O
the O
onset O
of O
cellular O
proliferation O
, O
levels O
of O
Id2 O
mRNA O
decrease O
while O
levels O
of O
Id3 O
mRNA O
increase O
, O
suggesting O
that O
regulation O
of O
expression O
of O
these O
closely O
related O
genes O
is O
disparate O
. O

Salicylates O
inhibit O
lipopolysaccharide-induced O
transcriptional O
activation O
of O
the O
tissue O
factor O
gene O
in O
human B
monocytic I
cells I
. O

TF O
expression O
by O
circulating B
monocytes I
is O
associated O
with O
thrombotic O
and O
inflammatory O
complications O
in O
a O
variety O
of O
diseases O
. O

Transcriptional O
activation O
of O
the O
human O
TF O
gene O
in O
monocytic B
cells I
exposed O
to O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
is O
mediated O
by O
binding O
of O
c-Rel/p65 O
heterodimers O
to O
a O
kappa O
B O
site O
in O
the O
TF O
promoter O
. O

Here O
, O
we O
report O
that O
a O
family O
of O
anti-inflammatory O
agents O
, O
known O
as O
the O
salicylates O
, O
inhibited O
LPS O
induction O
of O
TF O
activity O
and O
TF O
gene O
transcription O
in O
human B
monocytes I
and O
monocytic O
THP-1 O
cells O
at O
clinically O
relevant O
doses O
. O

These O
results O
indicated O
that O
salicylates O
inhibited O
LPS O
induction O
of O
TF O
gene O
transcription O
in O
monocytic B
cells I
by O
preventing O
nuclear O
translocation O
of O
c-Rel/p65 O
heterodimers O
. O

The O
activation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
( O
STAT O
) O
proteins O
in O
a O
primary O
TCR O
-mediated O
activation O
of O
T B
cells I
have O
been O
explored O
. O

In O
purified B
human I
peripheral I
blood I
T I
cells I
, O
nuclear O
STAT O
proteins O
were O
activated O
approximately O
3 O
h O
after O
activation O
by O
cross-linked O
anti-CD3 O
Abs O
. O

The O
induction O
of O
STAT O
activity O
was O
inhibited O
completely O
by O
pretreatment O
with O
either O
cycloheximide O
or O
cyclosporin O
A O
, O
thus O
indicating O
that O
the O
induction O
was O
due O
to O
a O
secondary O
factor O
produced O
by O
the O
activated O
T B
cells I
. O

The O
normal O
cell O
cycle O
activation O
program O
is O
exploited O
during O
the O
infection O
of O
quiescent B
B I
lymphocytes I
by O
Epstein-Barr O
virus O
. O

B B
lymphocytes I
in O
the O
peripheral O
circulation O
are O
maintained O
in O
a O
non-proliferative O
state O
. O

Because O
it O
is O
not O
clear O
at O
which O
point O
in O
cell O
cycle O
the O
peripheral B
B I
lymphocytes I
are O
arrested O
, O
we O
characterized O
the O
expression O
of O
several O
cell O
cycle-associated O
genes O
in O
quiescent B
and I
stimulated I
cells I
. O

Transient O
stimulation O
of O
quiescent B
B I
lymphocytes I
with O
either O
a O
cocktail O
of O
anti-CD40 O
, O
anti-IgM O
, O
and O
IL4 O
, O
or O
EBV O
results O
in O
the O
rapid O
expression O
of O
the O
same O
four O
genes O
, O
suggesting O
that O
, O
after O
infection O
, O
EBV O
exploits O
the O
normal O
program O
of O
B-lymphocyte B
cell O
cycle O
activation O
. O

In O
our O
attempt O
to O
identify O
chemokine O
receptors O
that O
are O
related O
to O
Burkitt O
's O
lymphoma O
receptor O
1 O
( O
BLR1 O
) O
and O
are O
expressed O
in O
activated B
lymphocytes I
we O
used O
RT-PCR O
resulting O
in O
the O
isolation O
of O
a O
cDNA O
encoding O
a O
seven O
transmembrane O
receptor O
termed O
BLR2 O
. O

Our O
data O
suggest O
an O
involvement O
of O
BLR2 O
in O
the O
regulation O
of O
migration O
in O
activated B
lymphocytes I
and O
in O
viral O
pathogenesis O
. O

A O
2.3-kb O
LCR O
in O
the O
human O
adenosine O
deaminase O
( O
ADA O
) O
gene O
first O
intron O
, O
which O
controls O
expression O
in O
thymocytes B
, O
is O
composed O
of O
a O
200-bp O
enhancer O
domain O
and O
extended O
flanking O
sequences O
that O
facilitate O
activation O
from O
within O
chromatin O
. O

c-Myb O
protein O
was O
strongly O
evident O
in O
T B
lymphoblasts I
in O
which O
the O
enhancer O
was O
active O
and O
was O
localized O
within O
discrete O
nuclear O
structures O
. O

Prior O
studies O
have O
identified O
several O
transcription O
factors O
that O
contribute O
to O
the O
activity O
of O
the O
IL-2 O
promoter O
in O
stimulated B
T I
lymphocytes I
. O

In O
unstimulated B
cells I
which O
do O
not O
secrete O
IL-2 O
, O
only O
Sp1 O
binds O
to O
this O
region O
, O
while O
in O
stimulated O
IL-2 O
secreting O
cells O
the O
inducible O
EGR-1 O
protein O
recognizes O
this O
element O
. O

Lymphoid O
enhancer-binding O
factor O
1 O
( O
LEF-1 O
) O
is O
a O
regulatory O
high O
mobility O
group O
( O
HMG O
) O
protein O
that O
activates O
the O
T O
cell O
receptor O
alpha O
( O
TCR O
alpha O
) O
enhancer O
in O
a O
context-restricted O
manner O
in O
T B
cells I
. O

HIV-1 O
envelope O
glycoproteins O
induce O
activation O
of O
activated O
protein-1 O
in O
CD4+ B
T I
cells I
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1995 O
Dec O
1 O
; O
270 O
( O
48 O
) O
: O
29038 O
] O

Activation O
of O
CD4 B
positive I
T I
cells I
is O
a O
primary O
requirement O
for O
human O
immunodeficiency O
virus O
( O
HIV O
) O
entry O
, O
efficient O
HIV O
replication O
, O
and O
progression O
to O
AIDS O
, O
Utilizing O
CD4 O
positive O
T O
cell O
lines O
and O
purified B
T I
cells I
from O
normal O
individuals O
, O
we O
have O
demonstrated O
that O
native O
envelope O
glycoproteins O
of O
HIV O
, O
gp O
160 O
, O
can O
induce O
activation O
of O
transcription O
factor O
, O
activated O
protein-1 O
( O
AP-1 O
) O
. O

This O
gp160 O
treatment O
adversely O
affects O
the O
functional O
capabilities O
of O
T B
cells I
: O
pre-treatment O
of O
CD4+ B
T I
cells I
with O
gp160 O
for O
4 O
h O
at O
37 O
degrees O
C O
inhibited O
anti-CD3 O
-induced O
interleukin-2 O
secretion O
. O

The O
aberrant O
activation O
of O
AP-1 O
by O
gp160 O
in O
CD4 B
positive I
T I
cells I
could O
result O
in O
up-regulation O
of O
cytokines O
containing O
AP-1 O
sites O
, O
e.g O
. O
interleukin-3 O
and O
granulocyte O
macrophage O
colony-stimulating O
factor O
, O
and O
concurrently O
lead O
to O
T B
cell I
unresponsiveness O
by O
inhibiting O
interleukin-2 O
secretion O
. O

